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METHODS FOR TREATING CONGESTIVE 
HEART FAILURE 
STATEMENT AS TO FEDERALLY SPONSORED 
al., Science 256:1205-1210, 1992), Acetylcholine Receptor 
Inducing Activity (ARIA, Falls et al., Cell 72301-815, 
1993), and the glial growth factors GGF1, GGF2, and GGF3 
(Marchionni et al. Nature 362:312-8, 1993). 
RESEARCH 5 The Nrg-2 gene was identified by homology cloning 
This work was supported in part by NIH Grants (Chang et al., Nature 387:509-512, 1997; Carraway et al., 
Biochem. 122:675-680, 1997) and through genomic 
approaches (Busfield et al., Mol. Cell. Biol. 17:4007-4014, 
10 1997). NRG-2 cDNAs are also known as Neural- and 
Thymus-Derived Activator of ErbB Kinases (NTAK, Gen- 
bank Accession No, AB005060), Divergent of Neuregulin 
(Don-1). and Cerebellum-Derived Growth Factor (CDGF; 
HL-38189, HL-36141, and a NASAaward, The government Nature 387:512-516, 1997; and Higashiyama et al., J.  
has certain rights in the invention. 
FIELD OF THE INVENTION 
The field Of the invention is treatment and prevention of 
congestive heart failure. 
BACKGROUND OF THE INVENTION 
PCT application WO 97109425). Experimental evidence 
15 shows that cells expressing ErbB4 or the ErbB2ErbB4 
Congestive heart failure, one of the leading causes of 
death in industrialized nations, results from an increased 
workload on the heart and a progressive decrease in its 
pumping ability. Initially, the increased workload that results 
from high blood pressure or loss of contractile tissue induces 2o 
compensatory cardiomyocyte hypertrophy and thickening of 
the left ventricular wall, thereby enhancing contractility and 
maintaining cardiac function. However, over time, the left 
ventricular chamber dilates, systolic pump function 
deteriorates, cardiomyocytes undergo apoptotic cell death, 25 
and myocardial function progressively deteriorates. 
Factors that underlie congestive heart failure include high 
blood pressure, ischemic heart disease, exposure to car- 
diotoxic compounds such as the anthracycline antibiotics, 3o 
and genetic defects known to increase the risk of heart 
failure. 
Neuregulins (NRGs) and NRG receptors comprise a 
growth factor-receptor tyrosine kinase system for cell-cell 
signalling that is involved in organogenesis in nerve, 35 
muscle, epithelia, and other tissues (Lemke, Mol. Cell. 
Neuvosci. 7:247-262, 1996 and Burden et al., Neuron 
18:847-855,1997). The NRG family consists of three genes 
that encode numerous ligands containing epidermal growth 
factor (EGF)-like, immunoglobulin (Ig), and other recog- 40 
nizable domains. At least 20 (perhaps 50 or more) secreted 
and membrane-attached isoforms may function as ligands in 
this signalling system. The receptors for NRG ligands are all 
members of the EGF receptor (EGFR) family, and include 
EGFR (or ErbBl), ErbB2, ErbB3, and ErbB4, also known as 45 
HER1 through HER4, respectively, in humans (Meyer et al., 
Development 124:3575-3586, 1997; Orr-Urtreger et al., 
Pvoc. Natl. Acad. Sci. USA 90: 1867-71, 1993; Marchionni 
et al., Nature 362:312-8, 1993; Chen et al., J.  Comp. Neuvol. 
349:389-400, 1994; Corfas et al., Neuron 14:103-115, 50 
1995; Meyer et  al., Pvoc. Natl .  Acad .  Sci.  USA 
91:1064-1068, 1994; and Pinkas-Kramarski et al., Onco- 
gene 15:2803-2815, 1997). We have found that neuregulins stimulate compensatory 
The three NRG genes, Nrg-1, Nrg-2, and Nrg-3, map to hypertrophic growth and inhibit apoptosis of myocardio- 
distinct chromosomal loci (Pinkas-Kramarski et al., Pvoc. 5s cytes subjected to physiological stress. Our observations 
Natl. Acad. Sei. USA 91:9387-91, 1994; Carraway et al., indicate that neuregulin treatment will be useful for 
Nature 387:512-516, 1997; Chang et  al., Nature preventing, minimizing, or reversing congestive heart dis- 
387:509-511, 1997; and Zhang et al., Pvoc. Natl. Acad. Sci. ease resulting from underlying factors such as hypertension, 
USA 94:9562-9567, 1997), and collectively encode a ischemic heart disease, and cardiotoxicity. 
diverse array of NRG proteins. The most thoroughly studied 60 The invention provides a method for treating or prevent- 
to date are the gene products of Nrg-1, which comprise a ing congestive heart failure in a mammal. The method 
group of approximately 15 distinct structurally-related iso- involves administering a polypeptide that contains an epi- 
forms (Lemke, Mol. Cell. Neuvosci. 7:247-262, 1996 and dermal growth factor-like (EGF-like) domain to the 
Peles and Yarden, BioEssays 15315-824, 1993). The first- mammal, wherein the EGF-like domain is encoded by a 
identified isoforms of NRG-1 included Neu Differentiation 65 neuregulin gene, and wherein administration of the polypep- 
Factor (NDF; Peles et al., Cell 69, 205-216, 1992 and Wen tide is in an amount effective to treat or prevent heart failure 
et al., Cell 69,559-572, 1992), Heregulin (HRG; Holmes et in the mammal. 
combination are likely to show a particularly robust 
response to NRG-2 (Pinkas-Kramarski et al., Mol. Cell. 
Biol. 18:6090-6101,1998). The Nrg-3 gene product (Zhang 
et al., supra) is also known to bind and activate ErbB4 
receptors (Hijazi etal., Znt. J .  Oncol. 13:1061-1067, 1998). 
An EGF-like domain is present at the core of all forms of 
NRGs, and is required for binding and activating ErbB 
receptors. Deduced amino acid sequences of the EGF-like 
domains encoded in the three genes are approximately 
3&40% identical (pairwise comparisons). Further, there 
appear to be at least two sub-forms of EGF-like domains in 
NRG-1 and NRG-2, which may confer different bioactivities 
and tissue-specific potencies. 
Cellular responses to NRGs are mediated through the 
NRG receptor tyrosine kinases EGFR, ErbB2, ErbB3, and 
ErbB4 of the epidermal growth factor receptor family. 
High-affinity binding of all NRGs is mediated principally 
via either ErbB3 or ErbB4. Binding of NRG ligands leads to 
dimerization with other ErbB subunits and transactivation 
by phosphorylation on specific tyrosine residues. In certain 
experimental settings, nearly all combinations of ErbB 
receptors appear to be capable of forming dimers in response 
to the binding of NRG-1 isoforms. However, it appears that 
ErbB2 is a preferred dimerization partner that may play an 
important role in stabilizing the ligand-receptor complex. 
Recent evidence has shown that expression of NRG-1, 
ErbB2, and ErbB4 is necessary for trabeculation of the 
ventricular myocardium during mouse development. 
In view of the high prevalence of congestive heart failure 
in the general population, it would be highly beneficial to 
prevent or minimize progression of this disease by inhibiting 
loss of cardiac function, and ideally, by improving cardiac 
function for those who have or are at risk for congestive 
heart failure. 
SUMMARY OF THE INVENTION 
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In various preferred embodiments of the invention, the 
neuregulin gene may be the NRG-1 gene, the NRG-2 gene, 
or the NRG-3 gene. Furthermore, the polypeptide may be 
encoded by any of these three neuregulin genes. Still further, 
the polypeptide used in the method may be recombinant 
human GGF2. 
In another preferred embodiment of the invention, the 
mammal is a human. 
In other embodiments of the invention, the congestive 
heart failure may result from hypertension, ischemic heart 
disease, exposure to a cardiotoxic compound (e.g., cocaine, 
alcohol, an anti-ErbB2 antibody or anti-HER antibody, such 
as HERCEPTINB, or an anthracycline antibiotic, such as 
doxorubicin or daunomycin), myocarditis, thyroid disease, 
viral infection, gingivitis, drug abuse; alcohol abuse, 
periocarditis, atherosclerosis, vascular disease, hypertrophic 
cardiomyopathy, acute myocardial infarction or previous 
myocardial infarction, left ventricular systolic dysfunction, 
coronary bypass surgery, starvation, an eating disorder, or a 
genetic defect. 
In another embodiment of the invention, an anti-ErB2 or 
anti-HER2 antibody, such as HERCEPTINB, is adminis- 
tered to the mammal either before, during, or after anthra- 
cycline administration. 
In other embodiments of the invention, the polypeptide 
containing an EGF-like domain encoded by a neuregulin 
gene is administered before, during, or after exposure to a 
cardiotoxic compound. In yet other embodiments, the 
polypeptide containing the EGF-like domain is administered 
during two, or all three, of these periods. 
In still other embodiments of the invention, the polypep- 
tide is administered either prior to or after the diagnosis of 
congestive heart failure in the mammal. 
In yet another embodiment of the invention, the polypep- 
tide is administered to a mammal that has undergone com- 
pensatory cardiac hypertrophy. 
In other preferred embodiments of the invention, admin- 
istration of the polypeptide maintains left ventricular 
hypertrophy, prevents progression of myocardial thinning, 
or inhibits cardiomyocyte apoptosis. 
In yet another embodiment of the invention, the polypep- 
tide may be administered by administering an expression 
vector encoding the polypeptide to the mammal. 
By “congestive heart failure” is meant impaired cardiac 
function that renders the heart unable to maintain the normal 
blood output at rest or with exercise, or to maintain a normal 
cardiac output in the setting of normal cardiac filling pres- 
sure. Aleft ventricular ejection fraction of about 40% or less 
is indicative of congestive heart failure (by way of 
comparison, an ejection fraction of about 60% percent is 
normal). Patients in congestive heart failure display well- 
known clinical symptoms and signs, such as tachypnea, 
pleural effusions, fatigue at rest or with exercise, contractile 
dysfunction, and edema. Congestive heart failure is readily 
diagnosed by well known methods (see, e.g., “Consensus 
recommendations for the management of chronic heart 
failure.” Am. J.  Cavdiol., 83(2A):lA-38-A, 1999). 
Relative severity and disease progression are assessed 
using well known methods, such as physical examination, 
echocardiography, radionuclide imaging, invasive hemody- 
namic monitoring, magnetic resonance angiography, and 
exercise treadmill testing coupled with oxygen uptake stud- 
ies. 
By “ischemic heart disease” is meant any disorder result- 
ing from an imbalance between the myocardial need for 
oxygen and the adequacy of the oxygen supply. Most cases 
of ischemic heart disease result from narrowing of the 
coronary arteries, as occurs in atherosclerosis or other vas- 
cular disorders. 
By “myocardial infarction” is meant a process by which 
ischemic disease results in a region of the myocardium being 
replaced by scar tissue. 
By “cardiotoxic” is meant a compound that decreases 
heart function by directing or indirectly impairing or killing 
By “hypertension” is meant blood pressure that is con- 
sidered by a medical professional (e.g., a physician or a 
nurse) to be higher than normal and to carry an increased 
risk for developing congestive heart failure. 
By “treating” is meant that administration of a neuregulin 
or neuregulin-like polypeptide slows or inhibits the progres- 
sion of congestive heart failure during the treatment, relative 
to the disease progression that would occur in the absence of 
treatment, in a statistically significant manner. Well known 
2o indicia such as left ventricular ejection fraction, exercise 
performance, and other clinical tests as enumerated above, 
as well as survival rates and hospitalization rates may be 
used to assess disease progression. Whether or not a treat- 
ment slows or inhibits disease progression in a statistically 
25 significant manner may be determined by methods that are 
well known in the art (see, e.g., SOLVD Investigators, N. 
Engl. J .  Med. 327:685-691, 1992 and Cohn et al., N. Engl. 
J Med. 339:1810-1816, 1998). 
By “preventing” is meant minimizing or partially or 
completely inhibiting the development of congestive heart 
failure in a mammal at risk for developing congestive heart 
failure (as defined in “Consensus recommendations for the 
management of chronic heart failure.” Am. J.  Cavdiol., 
83(2A):lA-38-A, 1999). Determination of whether conges- 
tive heart failure is minimized or prevented by administra- 
tion of a neurgulin or neuregulin-like polypeptide is made by 
known methods, such as those described in SOLVD 
Investigators, supra, and Cohn et al., supra. 
By “at risk for congestive heart failure” is meant an 
individual who smokes, is obese (i.e., 20% or more over 
their ideal weight), has been or will be exposed to a 
cardiotoxic compound (such as an anthracycline antibiotic), 
or has (or had) high blood pressure, ischemic heart disease, 
a myocardial infarct, a genetic defect known to increase the 
risk of heart failure, a family history of heart failure, 
myocardial hypertrophy, hypertrophic cardiomyopathy, left 
ventricular systolic dysfunction, coronary bypass surgery, 
vascular disease, atherosclerosis, alcoholism, periocarditis, a 
viral infection, gingivitis, or an eating disorder (e.g., anor- 
exia nervosa or bulimia), or is an alcoholic or cocaine addict. 
By “decreasing progression of myocardial thinning” is 
meant maintaining hypertrophy of ventricular cardiomyo- 
cytes such that the thickness of the ventricular wall is 
By “inhibits myocardial apoptosis” is meant that neuregu- 
lin treatment inhibits death of cardiomyocytes by at least 
lo%, more preferably by at least 15%, still more preferably 
by at least 25%, even more preferably by at least 50%, yet 
60 more preferably by at least 75%, and most preferably by at 
least 90%, compared to untreated cardiomyocytes. 
By “neuregulin” or “NRG’ is meant a polypeptide that is 
encoded by an NRG-1, NRG-2, or NRG-3 gene or nucleic 
acid (e.g., a cDNA), and binds to and activates ErbB2, 
By “neuregulin-1,” “NRG-1,” “heregulin,” “GGF2,” or 
“p185erbB2 ligand” is meant a polypeptide that binds to the 
5 
10 cardiomyocytes. 
30 
3s . 
40 . 
45 . 
55 maintained or increased. 
65 ErbB3, or ErbB4 receptors, or combinations thereof. 
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ErbB2 receptor and is encoded by the p185erbB2 ligand 
gene described in U.S. Pat. No. 5,530,109; U.S. Pat. No. 
5,716,930; and U.S. Ser. No. 081461,097. 
By “neuregulin-like polypeptide” is meant a polypeptide 
that possesses an EGF-like domain encoded by a neuregulin 
gene, and binds to and activates ErbB-2, ErbB-3, ErbB-4, or 
a combination thereof. 
By “epidermal growth factor-like domain” or “EGF-like 
domain” is meant a polypeptide motif encoded by the 
NRG-1, NRG-2, or NRG-3 gene that binds to and activates 
ErbB2, ErbB3, ErbB4, or combinations thereof, and bears a 
structural similarity to the EGF receptor-binding domain as 
disclosed in Holmes et al., Science 256:1205-1210, 1992; 
U.S. Pat. No. 5,530,109; U.S. Pat. No. 5,716,930; U.S. Ser. 
No. 081461,097; Hijazi et al., Znt. J .  Oncol. 13:1061-1067, 
1998; Chang et al., Nature 387:509-512, 1997; Carraway et 
al., Nature 387:512-516, 1997; Higashiyama et al., J Bio- 
chern. 122:675-680, 1997; and WO 97109425). 
By “anti-ErbB2 antibody” or “anti-HER2 antibody” is 
meant an antibody that specifically binds to the extracellular 
domain of the ErbB2 (also known as HER2 in humans) 
receptor and prevents the ErbB2 (HER2)-dependent signal 
transduction initiated by neuregulin binding. 
By “transformed cell” is meant a cell (or a descendent of 
a cell) into which a DNA molecule encoding a neuregulin or 
polypeptide having a neuregulin EGF-like domain has been 
introduced, by means of recombinant DNA techniques or 
known gene therapy techniques. 
By “promoter” is meant a minimal sequence sufficient to 
direct transcription. Also included in the invention are those 
promoter elements which are sufficient to render promoter- 
dependent gene expression controllable for cell type or 
physiological status (e.g., hypoxic versus normoxic 
conditions), or inducible by external signals or agents; such 
elements may be located in the 5’ or 3’ or internal regions of 
the native gene. 
By “operably linked” is meant that a nucleic acid encod- 
ing a polypeptide (e.g., a cDNA) and one or more regulatory 
sequences are connected in such a way as to permit gene 
expression when the appropriate molecules (e.g., transcrip- 
tional activator proteins) are bound to the regulatory 
sequences. 
By “expression vector” is meant a genetically engineered 
plasmid or virus,  derived from, for example,  a 
bacter iophage,  adenovirus ,  retrovirus,  poxvirus ,  
herpesvirus, or artificial chromosome, that is used to transfer 
a polypeptide (e.g., a neuregulin) coding sequence, operably 
linked to a promoter, into a host cell, such that the encoded 
peptide or polypeptide is expressed within the host cell. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1Ais  a representation of a semiquantitative RT-PCR 
analysis showing expression of neuregulin receptors during 
cardiac development and in adult rat cardiomyocytes. 
FIG. 1B is a representation of an assay showing tyrosine 
phosphorylation of the ErbB4 receptor in cardiomyocytes 
treated with recombinant human glial growth factor 2 
(rhGGF2). 
FIGS. 2A and 2B are representations of photomicrographs 
showing staining of neonatal rat ventricular myocytes for 
myosin heavy chain (FIG. 2A) and BrdU-positive nuclei 
(FIG. 2B). 
FIG. 2C is a graph showing that rhGGF2 stimulates DNA 
synthesis (indicated by % BrdU-positive myocytes) in neo- 
natal rat ventricular myocytes. 
6 
FIGS. 3A and 3B are graphs showing that rhGGF2 
stimulates DNA synthesis (indicated by % relative 
3H-thymidine uptake) in neonatal rat ventricular myocytes. 
FIG. 4 is a graph showing that ErbB2 and ErbB4 mediate 
5 the effects of GGF2 on relative 3H-thymidine uptake in 
neonatal rat ventricular myocytes. 
FIG. 5 is a graph showing that GGF2 promotes survival 
in primary cultures of neonatal rat ventricular myocytes. 
FIGS. 6A-6C and 6E-6G are representations of photo- 
micrographs showing that GGF2 diminishes apoptotic cell 
death in primary cultures of neonatal rat ventricular myo- 
cytes. 
FIG. 6D is a graph showing that rhGGF2 diminishes 
1~ apoptotic cell death in primary cultures of neonatal rat 
ventricular myocytes (indicated by a decrease in the per- 
centage of TUNEL-positive myocytes). 
FIG. 6H is a graph showing that rhGGF2 diminishes 
apoptotic cell death in primary cultures of neonatal rat 
20 ventricular myocytes (determined by flow cytometry analy- 
sis of the sub-G1 fraction following propidium iodide stain- 
ing of rhGGF2-treated cells). 
FIGS. 7A and 7B are graphs showing that rhGGF2 
increases survival and decreases apoptotic cell death in 
FIGS. SA and 8B are representations of photomicrographs 
showing that GGF2 induces hypertrophic growth of neonatal 
rat ventricular myocytes. 
FIG. 8C is a representation of a Northern blot showing 
that prepro-atrial natriuretic factor (prepro-ANF), a marker 
of ventricular hypertrophy, and a-skeletal actin are 
up-regulated in neonatal rat ventricular myocytes treated 
with GGF2. 
FIG. 8D is a graph showing that GGF2 stimulates protein 
synthesis (indicated by relative 3H-leucine uptake) in neo- 
natal rat ventricular myocytes. 
FIGS. 9A-9C are photomicrographs showing that GGF2 
induces hypertrophic growth in primary cultures of adult rat 
FIG. 9D is a representation of Northern blots showing that 
prepro-ANF and (x-skeletal actin are up-regulated in adult 
rat ventricular myocytes treated with GGF2. 
FIG. 9E is a graph showing that GGF2 stimulates protein 
45 synthesis (indicated by relative 3H-leucine uptake) in adult 
rat ventricular myocytes. 
FIGS. 1OA and 10B are representations of ribonuclease 
protection assays showing expression levels of ErbB2 (FIG. 
lOA), ErbB4 (FIG. lOB), and 0-actin in the left ventricles of 
control and aortic stenosis rat hearts. 
FIG. 11 is a representation of a Northern blot showing 
expression of ANF and glyceraldehyde phosphate dehydro- 
genase (GAPDH, a housekeeping gene) in myocytes from 
FIGS. 12A and 12B are representations of ribonuclease 
protection assays showing expression levels of ErbB2 (FIG. 
12A), ErbB4 (FIG. 12B), and 0-actin in myocytes from the 
left ventricles of control and aortic stenosis rat hearts. 
FIGS. 13A and 13B are representations of a Western blot 
showing expression levels of ErbB2 in 6-week (FIG. 13A) 
and 22-week (FIG. 13B) aortic stenosis and control rat 
hearts. 
FIGS. 13C and 13D are representations of a Western blot 
65 showing expression levels of ErbB2 in 6-week (FIG. 13C) 
and 22-week (FIG. 13D) aortic stenosis and control rat 
hearts. 
25 primary cultures of adult rat ventricular myocytes. 
3o 
35 
40 ventricular myocytes. 
55 left ventricles of control and aortic stenosis rat hearts. 
60 
US 6,635,249 B3 
7 
FIG. 14  is a graph showing that rat cardiomyocyte cul- 
tures pre-treated with IGF-1 or NRG-1 are less susceptible 
to daunorubicin-induced apoptosis. 
FIG. 15A is a representation of a phosphorylation assay 
showing that IGF- and NRG-1-stimulated phosphorylation 
of Akt is inhibited by the PI-3 kinase inhibitor wortmannin. 
FIG. 15B is a graph showing that IGF-1 and NRG-1 
inhibition of caspase 3 activation in cells exposed to dauno- 
rubicin is PI-3 kinase-dependent. 
DETAILED DESCRIPTION OF THE 
INVENTION 
We have found that neuregulins promote survival and 
hypertrophic growth of cultured cardiac myocytes through 
activation of ErbB2 and ErbB4 receptors. 
In addition, we have observed, in animals with 
experimentally-induced intracardiac pressure overload, that 
cardiomyocyte ErbB2 and ErbB4 levels are normal during 
early compensatory hypertrophy and decrease during the 
transition to early heart failure. 
Together, our in vitro and in vivo findings show that 
neuregulins are involved in stimulating compensatory 
hypertrophic growth in response to increased physiologic 
stress, as well as inhibiting apoptosis of myocardial cells 
subjected to such stress. These observations indicate that 
neuregulin treatment will be useful for preventing, 
minimizing, or reversing congestive heart disease. While not 
wishing to be bound by theory, it is likely that neuregulin 
treatment will strengthen the pumping ability of the heart by 
stimulating cardiomyocyte hypertrophy, and will partially or 
completely inhibit further deterioration of the heart by 
suppressing cardiomyocyte apoptosis. 
Neuregulins 
Polypeptides encoded by the NRG-1, NRG-2, and NRG-3 
genes possess EGF-like domains that allow them to bind to 
and activate ErbB receptors. Holmes et al. (Science 
256:1205-1210,1992) has shown that the EGF-like domain 
alone is sufficient to bind and activate the p185erbB2 
receptor. Accordingly, any polypeptide product encoded by 
the NRG-1, NRG-2, or NRG-3 gene, or any neuregulin-like 
polypeptide, e.g., a polypeptide having an EGF-like domain 
encoded by a neuregulin gene or cDNA (e.g., an EGF-like 
domain containing the NRG-1 peptide subdomains C-C/D 
or C-CID’, as described in U.S. Pat. No. 5,530,109, U.S. Pat. 
No. 5,716,930, and U.S. Ser. No. 081461,097; or an EGF- 
like domain as disclosed in WO 97109425) may be used in 
the methods of the invention to prevent or treat congestive 
heart failure. 
Risk Factors 
Risk factors that increase the likelihood of an individual’s 
developing congestive heart failure are well known. These 
include, and are not limited to, smoking, obesity, high blood 
pressure, ischemic heart disease, vascular disease, coronary 
bypass surgery, myocardial infarction, left ventricular sys- 
tolic dysfunction, exposure to cardiotoxic compounds 
(alcohol, drugs such as cocaine, and anthracycline antibiot- 
ics such as doxorubicin, and daunorubicin), viral infection, 
pericarditis, myocarditis, gingivitis, thyroid disease, genetic 
defects known to increase the risk of heart failure (such as 
those described in Bachinski and Roberts, Cardiol. Clin. 
16:603-610, 1998; Siu et al., Circulation 8:1022-1026, 
1999; and Arbustini et al., Heart 80:548-558, 1998), 
starvation, eating disorders such as anorexia and bulimia, 
family history of heart failure, and myocardial hypertrophy. 
8 
Accordingly, neuregulins may be administered to prevent 
or decrease the rate of congestive heart disease progression 
in those identified as being at risk. For example, neuregulin 
administration to a patient in early compensatory hypertro- 
s phy may permit maintenance of the hypertrophic state and 
may prevent the progression to heart failure. In addition, 
those identified to be at risk, as defined above, may be given 
cardioproctive neuregulin treatment prior to the develop- 
ment of compensatory hypertrophy. 
Neuregulin administration to cancer patients prior to and 
during anthracycline chemotherapy or anthracyclineianti- 
ErbB2 (anti-HER2) antibody (e.g., HERCEPTINB) combi- 
nation therapy may prevent the patients’ cardiomyocytes 
from undergoing apoptosis, thereby preserving cardiac func- 
15 tion. Patients who have already suffered cardiomyocyte loss 
may also derive benefit from neuregulin treatment, because 
the remaining myocardial tissue will respond to neuregulin 
exposure by displaying hypertrophic growth and increased 
contractility. 
10 
20 
Therapy 
Neuregulins and polypeptides containing EGF-like 
domains encoded by neuregulin genes may be administered 
to patients or experimental animals with a pharmaceutically- 
acceptable diluent, carrier, or excipient, in unit dosage form. 
Conventional pharmaceutical practice may be employed to 
provide suitable formulations or compositions to administer 
such compositions to patients or experimental animals. 
3o Although intravenous administration is preferred, any 
appropriate route of administration may be employed, for 
example, parenteral, subcutaneous, intramuscular, 
intracranial, intraorbital, ophthalmic, intraventricular, 
intracapsular, intraspinal, intracisternal, intraperitoneal, 
35 intranasal, aerosol, oral, or topical (e.g., by applying an 
adhesive patch carrying a formulation capable of crossing 
the dermis and entering the bloodstream) administration. 
Therapeutic formulations may be in the form of liquid 
solutions or suspensions; for oral administration, formula- 
tions may be in the form of tablets or capsules; and for 
intranasal formulations, in the form of powders, nasal drops, 
or aerosols. Any of the above formulations may be a 
sustained-release formulation. 
Methods well known in the art for making formulations 
45 are found in, for example, “Remington’s Pharmaceutical 
Sciences.” Formulations for parenteral administration may, 
for example, contain excipients, sterile water, or saline, 
polyalkylene glycols such as polyethylene glycol, oils of 
vegetable origin, or hydrogenated napthalenes. Sustained- 
release, biocompatible, biodegradable lactide polymer, 
lactideiglycolide copolymer,  or  polyoxyethylene- 
polyoxypropylene copolymers may be used to control the 
release of the compounds. Other potentially useful 
parenteral delivery systems for administering molecules of 
55 the invention include ethylene-vinyl acetate copolymer 
particles, osmotic pumps, implantable infusion systems, and 
liposomes. Formulations for inhalation may contain 
excipients, for example, lactose, or may be aqueous solu- 
tions containing, for example, polyoxyethylene-9-lauryl 
6o ether, glycocholate and deoxycholate, or may be oily solu- 
tions for administration in the form of nasal drops, or as a 
gel. 
2s 
40 . 
Gene Therapy 
Neuregulins and neuregulin-like polypeptides containing 
neuregulin EGF-like domains may also be administered by 
somatic gene therapy. Expression vectors for neuregulin 
65 
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gene therapy (e.g., plasmids, artificial chromosomes, or viral 
vectors, such as those derived from adenovirus, retrovirus, 
poxvirus, or herpesvirus) carry a neuregulin-encoding (or 
neuregulin-like polypeptide-encoding) DNA under the tran- 
scriptional regulation of an appropriate promoter. The pro- 
moter may be any non-tissue-specific promoter known in the 
art (for example, an SV-40 or cytomegalovirus promoter). 
Alternatively, the promoter may be a tissue-specific 
promoter, such as a striated muscle-specific, an atrial or 
ventricular cardiomyocyte-specific (e.g., as described in 
Franz et al., Cavdiovasc. Res. 35:560-566, 1997), or an 
endothelial cell-specific promoter. The promoter may be an 
inducible promoter, such as the ischemia-inducible promoter 
described in Prentice et al. (Cavdiovasc. Res. 35:567-574, 
1997). The promoter may also be an endogenous neuregulin 
promoter. 
The expression vector may be administered as naked 
DNA mixed with or conjugated to an agent to enhance the 
entry of the DNA into cells, e.g., a cationic lipid such as 
LipofectinTM, LipofectamineTM (GibcoiBRL, Bethesda, 
Md.), DOTAPTM (Boeringer-Mannheim, Indianapolis, Ind.) 
or analogous compounds, liposomes, or an antibody that 
targets the DNA to a particular type of cell, e.g., a cardi- 
omyocyte or an endothelial cell. The method of administra- 
tion may be any of those described in the Therapy section 
above. In particular, DNAfor somatic gene therapy has been 
successfully delivered to the heart by intravenous injection, 
cardiac perfusion, and direct injection into the myocardium 
(e.g., see Losordo et al., Circulation 98:2800-2804, 1998; 
Lin et al., Hypertension 33:219-224, 1999; Labhasetwar et 
al., J .  Phavm. Sci. 87:1347-1350, 1998; Yayama et al., 
Hypertension 31:1104-1110,1998). The therapeutic DNAis 
administered such that it enters the patient's cells and is 
expressed, and the vector-encoded therapeutic polypeptide 
binds to and activates cardiomyocyte ErbB receptors. 
The following Examples will assist those skilled in the art 
to better understand the invention and its principles and 
advantages. It is intended that these Examples be illustrative 
of the invention and not limit the scope thereof. 
EXAMPLE I 
General Methods 
Preparation of Cardiac Myocyte and Non-Myocyte Pri- 
mary Cultures Neonatal rat ventricular myocyte (NRVM) 
primary cultures were prepared as described previously 
(Springhorn et al., J .  Biol. Chem. 267:14360-14365, 1992). 
To selectively enrich for myocytes, dissociated cells were 
centriffuged twice at 500 rpm for 5 min, pre-plated twice for 
75 min, and finally plated at low density (0.7-1x104 cells/ 
cm') in Dulbecco's modified Eagle's (DME) medium (Life 
Technologies Inc., Caithersburg, Md.) supplemented with 
7% fetal bovine serum (FBS) (Sigma, St. Louis, Mo.). 
Cytosine arabinoside (AraC; 10 pM; Sigma) was added to 
cultures during the first 24-48 h to prevent proliferation of 
non-myocytes, with the exception of cultures used for thy- 
midine uptake measurements. Unless otherwise stated, all 
experiments were performed 36-48 h after changing to a 
serum-free medium, DME plus ITS (insulin, transferrin, and 
selenium; Sigma). Using this method, we routinely obtained 
primary cultures with >95% myocytes, as assessed by 
microscopic observation of spontaneous contraction and by 
immunofluorescence staining with a monoclonal anti- 
cardiac myosin heavy chain antibody (anti-MHC; 
Biogenesis, Sandown, N.H.). 
Primary cultures of cellular fractions isolated from neo- 
natal hearts enriched in non-myocyte cells were prepared by 
10 
twice passaging cells that adhered to the tissue culture dish 
during the preplating procedure. These non-myocyte 
cultures, which contained few anti-MHC-positive cells, 
were allowed to grow to subconfluence in DME supple- 
s mented with 20% FBS before switching to DME-ITS for a 
subsequent 36 to 48 h. 
Isolation and preparation of adult rat ventricular myocyte 
(ARVM) primary cultures was carried out using techniques 
previously described (Berger et al., Am. J .  Physiol. 
i o  266:H341-H349,1994). Rod-shaped cardiac myocytes were 
plated in culture medium on laminin-(10 pg/ml; Collabo- 
rative Research, Bedford, MA) precoated dishes for 60 min, 
followed by one change of medium to remove loosely 
attached cells. The contamination of ARVM primary cul- 
is tures by non-myocytes was determined by counting with a 
haemocytometer and was typically less than 5%. All ARVM 
primary cultures were maintained in a defined medium 
termed "ACCITT" (Ellingsen et al., Am. J .  Physiol. 
265:H747-H754, 1993) composed of DME, supplemented 
20 with 2 mgiml BSA, 2 mM L-carnitine, 5 mM creatine, 5 mM 
taurine, 0.1 pM insulin, and 10 nM truiodothyronine with 
100 IUiml penicillin and 100 pgiml streptomycin. In experi- 
mental protocols designed to examine myocyte survival 
and/or apoptosis, insulin was omitted from the defined 
zs medium, which is therefore termed "ACCTT". 
PCR Analysis of ErbB Receptors in Rat Heart 
cDNA sequences encoding portions of the C-termini of 
ErbB receptors were amplified by using the following syn- 
t h e t i c  o l i g o n u c l e o t i d e  p r i m e r s :  E r b B 2 A  ( 5 ' -  
30 TGTGCTAGTCAAGAGTCCCAACCAC-3': sense; SEQ 
I D  N O :  1) a n d  E r b B 2 B  ( 5 ' -  
CCTTCTCTCGGTACTAAGTATTCAG-3': antisense; SEQ 
ID NO: 2) for amplification of ErbB2 codon positions 857 
to 1207 (Bargmann et al., Nature 319:226-230, 1986); 
3s ErbB3A (5'-GCTTAAAGTGCTTGGCTCGGGTGTC-3': 
s e n s e ;  S E Q  I D  N O :  3) a n d  E r b B 3 B  ( 5 ' -  
TCCTACACACTGACACTTTCTCTT-3': antisense; SEQ 
ID NO: 4) for amplification of ErbB3 codon positions 712 
to 1085 (Kraus et al., Pvoc. Natl. Acad. Sci. USA 
40 8 6 : 9 1 9 3 - 9 1 9 7 ,  1 9 8 9 ) ;  E r b B 4 A  ( 5 ' -  
AATTCACCCATCAGAGTGACGTTTGG-3': sense; SEQ 
I D  N O :  5) a n d  E r b B 4 B  ( 5 ' -  
TCCTGCAGGTAGTCTGGGTGCTG: antisense; SEQ ID 
NO: 6) for amplification of ErbB4 codon positions 896 to 
4s 1262 (Plowman et al., Pvoc. Natl. Acad. Sci. USA 
90:1746-1750, 1993). RNA samples (1 pg) from rat hearts 
or freshly isolated neonatal and adult rat ventricular myo- 
cytes were reverse-transcribed to generate first-strand 
cDNA. The PCR reactions were performed in a final volume 
SO of 50 pl containing approximately 50 ng of first-strand 
cDNAs for thirty cycles in a PTC-100TM Programmable 
Thermal Controller (MJ Research, Inc.; Watertown, Mass.). 
Each cycle included 30 sec at 94" C., 75 sec at 63" C., and 
120 sec at 72" C. Thirty pl  aliquots of each reaction mixture 
ss were analyzed by electrophoresis in 1% agarose gels and by 
ethidium bromide staining. The PCR products were directly 
cloned into the TA cloning vector (Invitrogen Co., San 
Diego, Calif.) and verified by automatic DNA sequencing. 
Analysis of ErbB Receptor Phosphorylation 
60 To analyze which receptor subtypes were tyrosine- 
phosphorylated, neonatal and adult ventricular myocyte 
cells were maintained in serum-free medium for 24 to 48 h, 
and then treated with recombinant human glial growth factor 
2 (rhGGF2) at 20 ngiml for 5 min at 37" C. Cells were 
65 quickly rinsed twice with ice-cold phosphate-buffered saline 
(PBS) and lysed in cold lysis buffer containing 1% NP40,50 
mM Tris-HC1 (pH 7.4), 150 mM NaC1, 1 mM ethylene 
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glycol-bis(0-aminoethyl ether)-N, N, N', N'-tetraacetic acid 
(EGTA), 1 mM ethylenediaminetetraacetic acid (EDTA), 
0.5% sodium deoxycholate, 0.1% SDS, 1 mM sodium 
orthovanadate, 10 mM sodium molybdate, 8.8 g/L sodium 
pyrophosphate, 4 giL NaF1, 1 mM phenylmethylsulfonyl 
fluoride (PMSF), 10 pgiml aprotinin, and 20 pM leupeptin. 
Lysates were centrifuged at 12,OOOxg at 4" C. for 20 min, 
and aliquots of 500pg (neonatal myocytes) or 2000pg (adult 
myocytes) of supernatant were incubated with antibody 
specific to ErbB2 or ErbB4 (Santa Cruz Biotechnology Inc., 
Santa Cruz, Calif.) overnight at 4" C. and precipitated with 
protein A-agarose (Santa Cruz Biotechnology, Inc.). Immu- 
noprecipitates were collected and released by boiling in 
sodium dodecyl sulfate (SDS) sample buffer. Samples were 
fractionated by SDS-polyacrylamide gel electrophoresis 
(SDS-PAGE), transferred to polyvinylidene difluoride 
(PVDF) membranes (Biorad Laboratories, Hercules, Calif.) 
and probed with a PY20 antiphosphotyrosine antibody 
(Santa Cruz Biotechnology, Inc.). For detection of ErbB2, 
the supernatants were also immunoprecipitated with a bioti- 
nylated RC20 antiphosphotyrosine antibody (Upstate 
Biotechnology, Inc., Lake Placid, N.Y.) and blotted with a 
monoclonal antibody to ErbB2 (Ab-2; Oncogene Research 
Products, Cambridge, Mass.). 
Incorporation of [3H]Thymidine and [3H]Leucine 
As an index of DNA synthesis, [3H]thymidine incorpo- 
ration was measured as described previously (Berk et al., 
Hypertension 13:305-314, 1989). After incubation for 36 to 
48 h in serum-free medium (DME plus ITS), the cells were 
stimulated with different concentrations of rhGGF2 
(Cambridge Neuroscience Co., Cambridge, Mass.) for 20 h. 
[3H]thymidine (0.7 Ciimmol; Dupont) was then added to the 
medium at a concentration of 5 pCiiml and the cells were 
cultured for another 8 h. Cells were washed with PBS twice, 
10% TCA once, and 10% TCA was added to precipitate 
protein at 4" C. for 45 min. Parallel cultures of myocytes not 
exposed to rhGGF2 were harvested under the same condi- 
tions as controls. The precipitate was washed twice with 
95% ethanol, resuspended in 0.15 N NaOH and saturated 
with 1 M HC1, then aliquots were counted in a scintillation 
counter. The results are expressed as relative cpmidish 
normalized to the mean cpm of control cells in each experi- 
ment. For antibody blocking experiments, the same proce- 
dure was applied except that the cells were preincubated 
with an antibody (0.5 giml) specific for each neuregulin 
receptor (c-neu Ab-2, Oncogene Research Products; and 
ErbB3 or ErbB4, Santa Cruz Biotechnology), for 2 h prior 
to addition of either rhGGF2 or rhFGF2. 
The rate of [3H]leucine uptake was used as an index of 
protein synthesis. For these experiments, 10 pM cytosine 
arabinoside was added to the culture medium. Cells were 
grown in serum-free medium for 36 to 48 h and then 
stimulated with different doses of rhGGF2. After 40 h, 
[3H]leucine (5 pCiiml) was added for 8 h, and cells were 
washed with PBS and harvested with 10% TCA. TCA- 
precipitable radioactivity was determined by scintillation 
counting as above. 
5-Bronmo-2'-Deoxy-Uridine Incorporation and Immunof- 
luorescence Staining 
Nuclear 5-bromo-2'-deoxy-uridine (BrdU) incorporation 
and a cardiac muscle-specific antigen, myosin heavy chain 
(MHC), were simultaneously visualized using double- 
indirect immunofluorescence. Primary NRVM cultures were 
maintained in DME plus ITS for 48 h and then stimulated 
with rhGGF2 (40 ngiml) for 30 h. Control cultures were 
prepared similarly but without rhGGF2. BrdU (10 pM) was 
added for the last 24 h. Cells were fixed in a solution of 70% 
12 
ethanol in 50 mM glycine buffer, pH 2.0, for 30 min at -20" 
C., rehydrated in PBS and incubated in 4 N HC1 for 20 min. 
Cells were then neutralized with three washes in PBS, 
incubated with 1% FBS for 15 min, followed by a mouse 
s monoclonal anti-MHC (1:300; Biogenesis, Sandown, N.H.) 
for 60 min at 37" C. The primary antibody was detected with 
TRITC-conjugated goat anti-mouse IgG (1:300, The Jack- 
son Laboratory, Bar Harbor, Me.), and nuclear BrdU incor- 
poration was detected with fluorescein-conjugated anti- 
i o  BrdU antibody from an in situ cell proliferation kit 
(Boehringer Mannheim Co. Indianapolis, Ind.). The cover- 
slips were mounted with Flu-mount (Fisher Scientific; 
Pittsburgh, Pa.), and examined by immunofluorescence 
microscopy. About 500 myocytes were counted in each 
is coverslip and the percentage of BrdU-positive myocytes was 
calculated. 
For examination of changes in myocyte phenotype with 
rhGGF2, cells were fixed in 4% (wiv) paraformaldehyde for 
30 min at room temperature, rinsed with PBS, permeabilized 
20 with 0.1% Triton X-100 for 15 min, and then incubated with 
1% FBS for another 15 min, followed by incubation with 
anti-MHC (1:300) and visualized with TRITC-conjugated 
(NRVM) or FITC-conjugated (ARVM) second antibody. 
ARVM were examined using a MRC 600 confocal micro- 
25 scope (BioRad; Hercules, Calif.) with a KriAr laser. 
Cell Survival Assay And Detection of Apoptosis 
Cell viability was  deter-mined by the 3-(4,5- 
dimethylthiazo1-2-yl)-2,5-diphenyl tetrazolium bromide 
(MTT, Sigma) cell respiration assay, which is dependent on 
mitochondrial activity in living cells (Mosman, J.  Zmmunol. 
Meth. 65:55-63, 1983). Primary cultures of NRVM after 2 
days in serum-free medium were stimulated with different 
concentrations of rhGGF2 for either 4 or 6 days. ARVM 
35 were maintained in ACCTT medium or ACCTT medium 
plus different concentrations of rhGGF2 for 6 days. MTT 
was then incubated with the cells for 3 h at 37" C. Living 
cells transform the tetrazolium ring into dark blue formazan 
crystals that can be quantified by reading the optical density 
4o at 570 nm after cell lysis with dimethylsulfoxide (DMSO; 
Sigma). 
Apoptosis was detected in neonatal and adult myocytes 
using the terminal deoxynucleotidyltransferase (TdT)- 
mediated dUTP nick end-labeling (TUNEL) assay. 3'-end 
45 labelling of DNA with fluorescein-conjugated dUTP was 
done using an in situ cell death detection kit (Boehringer 
Mannheim, Indianapolis, IN) following the manufacturer's 
instructions. Cells were counterstained with an anti-MHC 
antibody as described above, and the nuclei were also 
so stained with Hoescht 33258 (lOpM, Sigma) for 5 min. More 
than 500 myocytes were counted in each coverslip and the 
percentage of TUNEL positive myocytes was calculated. 
Flow cytometric analysis of neonatal myocytes fixed in 
70% ethanoliPBS and stained with propidium iodide was 
ss also performed to quantify the percentage of cells undergo- 
ing apoptosis. This method is based upon the observation 
that cells undergoing apoptosis have a hypo-diploid quantity 
of DNA and localize in a broad area below the GOiGl peak 
on a DNA histogram. Briefly, cells were collected by 
60 trypsinization, pooled with nonattached cells, and fixed in 
70% ethanol. After being rinsed once with PBS, cells were 
incubated with a propidium iodide (20 pgiml, Sigma) solu- 
tion containing RNase A (5 Kunitz unitsiml) at room tem- 
perature for 30 min. Data were collected using a FACScan 
65 (Becton-Dickinson, San Jose, Calif.). For each sample, 
10,000 events were collected. Aggregated cells and 
extremely small cellular debris were gated out. 
30 
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Isolation and Hybridization of RNA and von Willebrand Factor (pAb, Sigma, 1:200) to distin- 
Total cellular RNA was isolated by a modification of the guish between myocytes and endothelial cells. Secondary 
acid guanidiniumithiocyanate phenolichloroform extraction antibodies (goat anti-rabbit, goat anti-mouse pAb, Molecu- 
method (Chomczynski and Sacchi, Anal. Biochem. lar Probes, 11400) with a Texas Red (Or Oregon Green) 
162:156-159, 1987) using the TRIZOL reagent (Life Tech- s conjugate were used as a detection system. NinetY-eight 
nologies I ~ ~ , ,  ~ ~ i t h ~ ~ ~ b ~ ~ ~ ,  ~ d , ) ,  RNA was size- percent myocytes and less than 2% fragments of endothelial 
fractionated by formaldehyde agarose gel e~ectrophoresis, cells or unstained cells (fibroblasts) were routinely obtained. 
transferred to nylon filters (Dupont, Boston, Mass.) by RNA 
overnight capillary blotting and hybridized with cDNA RNA was from and hypertrophied 
probes labelled with [a-32P]dCTP by random priming (Life 10 myocytes (n=10 hearts in each group), and from Lv tissue 
(n=10 hearts in each group) using TRI Reagent (Sigma). 
Tissue and myocyte RNA were used for the following 
protocols. Using myocyte RNA, Northern blots were used to 
Technologies Inc.). The filters were washed under stringent 
conditions and exposed to X-ray X-omat AR2 
Rochester, N.y.). intensity was determined by den- 
sitometry (Ultrascan XL, Pharmacia). The following cDNA 
assess message levels of atrial natriuretic peptide which 
were normalized to GAPDH (Feldman et al,, Circ, Res, 
probes were used: rat prepro-atrial natriuretic factor (prepro- 15 73: 184-192 1993. ~ ~ j i ~ ~  et circulation 99: 127-135
N F ;  a marker of CardiomYOcYte hypertrophy) (0.6 kb of 1999). Thesk expe;iments were &one to conirm the speci; 
coding region) (Seidman, et al., Science 225:324-326, ficity of myocyte origin of the RNA using this molecular 
1984), and rat skeletal a-actin (240 bp of a 3'-untranslated marker of hypertrophy. 
region) (Shani et al., Nucleic Acids Res. 9:579-589, 1981). We also performed reverse transcription-polymerase 
Arat glyceraldehyde-3-phosphate dehydrogenase (GAPDH; 20 chain reactions (RT-PCRs) for initial estimation of the 
a housekeeping gene) cDNA probe (240 bp of the coding presence of ErbB2, ErbB4 and neuregulin in samples 
region) (Tso et al., Nucleic Acids Res. 13:2485-2502, 1985) derived from adult rat heart and adult myocytes using the 
was used as control for loading and transfer efficiency. following pairs of primers: ErbB2 sense 5' GCT GGC TCC 
Aortic Stenosis Model GAT GTA TTT GAT GGT 3' (SEQ ID NO: 7), ErbB2 
Ascending aortic stenosis was performed in male Wistar zs antisense 5' GTT CTC TGC CGT AGG TGT CCC TTT 3' 
weanling rats (body weight 50-70 g, 3-4 weeks, obtained (SEQ ID NO: 8) (Sarkar et al., Diagn. Mol. Pathol. 
from Charles River Breeding Laboratories, Wilmington, 2:210-218, 1993); ErbB3 sense 5' GCT TAA AGT GCT 
Mass.), as previously described (Schunkert et al., TGG CTC GGG TGTC 3' (SEQ ID NO: 3), ErbB3 antisense 
Circulation, 87:1328-1339, 1993; Weinberg et al. 5' TCC TAC ACA CTG ACA CTT TCT CTT 3' (SEQ ID 
Circulation, 90:141&1422,1994; Feldman et al., Circ. Res., 30 NO: 4) (Kraus et al., Proc. Natl. Acad. Sci. USA 
73:184-192, 1993; Schunkert et al., J .  Clin. Invest. 86:9193-9197; 1989), ErbB4 sense 5' AAT TCA CCC ATC 
96:2768-2774, 1995; Weinberg et al., Circulation, AGA GTG ACG TTT GG 3' (SEQ ID NO: 5), ErbB4 
95:1592-1600, 1997; Litwin et al.,  Circulation, antisense 5' TCC TGC AGG TAG TCT GGG TGC TG 3' 
91:2642-2654; 1995). Sham-operated animals served as (SEQ ID NO: 6) (Plowman et al., Proc. Natl. Acad. Sci. USA 
age-matched controls. Aortic stenosis animals and age- 35 90:1746-1750; 1993); neuregulin sense 5' GCA TCA CTG 
matched sham-operated controls were sacrificed after anes- GCT GAT TCT GGA G 3' (SEQ ID NO: 9), neuregulin 
thesia with intraperitoneal pentobarbital 65 mg/kg at 6 and antisense 5" CAC ATG CCG GTT ATG GTC AGC A 3' 
22 weeks after surgery (n=2&29 per group). Hemodynamic (SEQ ID NO: 10). The latter primers recognize nucleic acids 
and echocardiographic studies in this model have shown that encoded by the NRG-1 gene, but do not discriminate 
compensatory hypertrophy with normal left ventricular (LV) 40 between its isoforms. The amplification was initiated by 1 
cavity dimensions and contractile indices is present 6 weeks min of denaturation, 2 min of annealing at the gene specific 
after banding, whereas animals develop early failure by 22 temperature and 2 min extension at 72" C. The whole PCR 
weeks after banding, which is characterized by onset of LV reaction was electrophoresed on a 1% agarose gel and the 
cavity enlargement and mild depression of ejection indices PCR products of expected size were gel-purified. 
and pressure development per gram LV mass. In the present 45 After cloning these fragments into pGEM-T vector 
study, in vivo LV pressure measurements were performed (Promega, Madison, Wis.), the correctness and orientation of 
prior to sacrifice as previously described (Schunkert et al., those fragments within the vector was confirmed by 
Circulation, 87:1328-1339, 1993; Weinberg et al. sequencing. Cloned PCR fragments were used to generate a 
Circulation, 90:141&1422,1994; Feldman et al., Circ. Res., radiolabeled riboprobe using the MAXIscript in vitro tran- 
73:184-192, 1993; Schunkert et al., J .  Clin. Invest. S O  scription kit (Ambion, Inc., Austin, Tex.) and a-32P-UTP. 
96:2768-2774, 1995; Weinberg et al., Circulation, The plasmids containing the ErbB2, ErbB4 or neuregulin 
95:1592-1600, 1997; Litwin et al.,  Circulation, fragment were linearized and a radiolabeled probe was 
91:2642-2654; 1995). The animals were also inspected for synthesized by in vitro transcription with T7 or T3 RNA 
clinical markers of heart failure, including the presence of polymerase. The 0-actin probe provided by the kit was 
tachypnea, ascites, and pleural effusions. Both body weight ss transcribed with T7 or T3 polymerase and resulted in a 330 
and LV weight were recorded. and 300 bp fragment, respectively. 20 pg of total RNA was 
LV Myocyte Isolation for RNA Extraction hybridized to 5x10' cpm of ErbB2, ErbB4 or neuregulin 
In a subset of animals (n=10 per group), the heart was c-RNA together with 2x104 cpm of 0-actin for later nor- 
rapidly excised and attached to an aortic cannula. Myocyte malization according to the RPA I1 kit (Ambion) protocol. 
dissociation by collagenase perfusion was performed as 60 After digestion with RNase AiRNase T1, the samples 
previously described (Kagaya et al., Circulation, were precipitated, dried, redissolved and finally separated on 
94:2915-2922, 1996; Ito et al., J .  Clin. Invest. 99:125-135, a 5% polyacrylamide gel for 2 hours. The gel was exposed 
1997; Tajima et al., Circulation, 99:127-135, 1999). To to Kodak MR film for 12-48 hours, and the assay was 
evalulate the percentage of myocytes in the final cell quantified by densitometric scanning of the auto-radiograph 
suspension, aliquots of myocytes were fixed, permeabilized 65 using Image Quant software (Molecular Dynamics, Inc., 
and blocked. The cell suspension was then incubated with Sunnyvale, Calif.). ErbB2, ErbB4 and neuregulin mRNA 
antibodies against a-sarcomeric actin (mAb, Sigma, 1:20) levels were normalized to 0-actin. 
US 6,635,249 B1 
15 16 
Western Blotting of ErbB2 and ErbB4 applied to each section until a blue-colored reaction became 
LV tissue (n=5 hearts per group) was rapidly homog- visible. The reaction was stopped and the slides were 
enized in a RIPA buffer containing 50 mmol/L Tris HC1, pH washed in PBS and distilled water for 5 minutes each. After 
7.4, 1% NP-40, 0.1% SDS, 0.25% Na-deoxycholate, 150 a nuclear counter-staining the sections were dehydrated 
mM NaC1, 1 mM EDTA, 1 mM PMSF, 1 pgiml Aprotinin, s through an ethanol series, immersed in xylene and mounted 
1 pgiml leupeptin, 1 pgiml pepstatin and 1 mM Na,P04. by cover-slipping in Permount. 
Proteins were quantified using the Lowry assay kit (Sigma). Statistical Analysis 
50 pg of protein in Laemmli SDS sample buffer were boiled All values are expressed as mean+SEM. Statistical analy- 
for 5 minutes and after centrifugation loaded onto a 10% sis of differences observed between the aortic stenosis 
SDS-PAGE gel. After electrophoresis, proteins were trans- i o  groups (6 and 22 weeks after banding) and the age-matched 
ferred to a nitrocellulose membrane at 100 mA overnight. control groups was done by ANOVA comparison. An 
The filters were blocked with 0.05% Tween-20, 5% nonfat unpaired Student's test was used for comparison among the 
milk and then incubated with anti-ErbB2 or anti-ErbB4 groups at the same age post-banding. Statistical significance 
(Santa Cruz Biotechnology, each diluted 1:100, 1 pgiml). was accepted at the level of pe0.05. 
EXAMPLE I1 After incubation with goat anti-rabbit peroxidase- is conjugated secondary antibody diluted 1:2000, blots were 
subjected to the enhanced chemiluminescent (ECL) detec- Neuregulins Promote Survival and Growth of 
tion method (Amersham, Life Science) and afterwards Cardiac Myocytes 
exposed to Kodak MR film for 3Ck180 seconds. Protein Expression of Neuregulin Receptors in the Heart 
levels were normalized to protein levels of 0-actin detected 20 To determine which of the NRG receptors (i.e., ErbB2, 
with anti-0-actin (Sigma). ErbB3, ErbB4) are expressed in rat myocardium, RNAfrom 
In Situ Hybridization for Neuregulin rat heart tissues at successive stages of development, and 
10-pm cryostat sections of left ventricular tissue (n=2 from freshly isolated neonatal and adult ventricular 
control and 6-week aortic stenosis hearts) were used for in myocytes, were reverse-transcribed and amplified by PCR, 
situ hybridizations. Antisense and sense RNA probe was zs using primers that flank the variable C-termini of ErbB 
synthesized from cDNAfragments in pBluescript with either receptors. FIG. 1 A  shows the semiquantitative RT-PCR 
T7 or T3 RNA polymerase and digoxigenin-labeled UTP analysis of neuregulin receptor mRNA levels during cardiac 
(DIG RNA Labeling Mix, Boehringer Mannheim). Tissue development. Total RNA from embryonic (E14, E16, and 
sections were first treated with 4% paraformaldehyde for 20 E19), neonatal (Pl) or adult (Ad) rat heart, and from freshly 
minutes, followed by 30 minutes digestion with proteinase 30 isolated neonatal rat ventricular myocytes (NRVM) or adult 
K (10 pgiml) at 37" C. and another 5 minutes of fixation in rat ventricular myocytes (ARVM) was reverse-transcribed 
4% paraformaldehyde. into cDNA and amplified with receptor isoform-specific 
Following the fixation, the slides were washed in PBS primers (see Methods). GAPDH was used as a control for 
three times for 5 minutes, after which the sections were reverse transcription, PCR amplification, and gel loading 
immersed in 0.1 M triethanolamine chloride buffer with 3s ("M' denotes 1 kb or 120 bp DNA molecular weight 
0.25% acetic anhydride for 10 minutes to block polar and standards). The RT-PCR products were verified by DNA 
charged groups on the section and hence prevent nonspecific sequencing. 
probe binding. After washing the slides in 2xSSC, they were All three ErbB receptors were expressed in the developing 
then prehybridized (50% formamide, 2xSSC, 5% rat heart at mid-embryogenesis (E14), with the following 
dextransulfate, 0.1% SDS, IxDenhardt's, 400 pgiml dena- 40 rank order of their relative mRNA abundances:  
tured salmon sperm DNA) at 45" C. for 60 minutes in a ErbB4>ErbB2>ErbB3. The expression of ErbB receptors 
moist chamber charged with 50% formamidei2X SSC. After was down-regulated later in embryogenesis. At E16 and 
1 hour, the probes were added to the prehybridization E19, and at post-natal day 1 (Pl), only ErbB2 and ErbB4 
solution and the slides were hybridized for 16-18 hours at mRNAs could be detected. In adult rat heart, ErbB4 was still 
45" c .  4s detectable, but its mRNA abundance was lower than that 
Following overnight hybridization, slides were twice detected in embryonic and neonatal hearts, whereas ErbB2 
washed in 4xSSC for 30 minutes at 45" C. while shaking, mRNA and, rarely, ErbB3 mRNA could be detected only at 
and then incubated with RNaseA (40 pgiml) in 500 mM low levels in adult myocardium. In freshly isolated neonatal 
NaC1, 10 mM Tris, 1 mM EDTA, pH 8.0, for 30 minutes at and adult rat ventricular myocyte primary cultures, both 
37" C. to remove unhybridized probe. After RNase SO ErbB2 and ErbB4 mRNA were readily detectable by 
treatment, sections were immersed in 2xSSC at 50" C. for 30 RT-PCR, although ErbB4 expression levels were consis- 
minutes and then in 0.2xSSC at the same temperature for tently higher than those of ErbB2. Furthermore, when using 
another 30 minutes. The slides were equilibrated with TBS receptor-specific cDNA probes for ErbB2, ErbB3 and 
I buffer (100 mM Tris, 150 mM NaC1, pH 7.5) and then ErbB4, only transcripts for ErbB4 were readily detectable in 
blocked with blocking reagent for 30 minutes at room ss freshly isolated neonatal and adult rat ventricular myocytes 
temperature according to the manufacturer's protocol (DIG by Northern blot. 
Nucleic Acid Detection Kit, Boehringer Mannheim). To determine which of the ErbB receptors were tyrosine- 
After removing the blocking reagent, the slides were phosphorylated following neuregulin treatment, primary 
immersed in TBS I for 1 minute and then the anti-DIG-AP cultures of NRVM or ARVM, maintained in serum-free 
conjugate solution (DIG Nucleic Acid Detection Kit, Boe- 60 medium for 24 to 48 h, were treated either with or without 
hringer Mannheim) was applied to each section for 1.5 hours neuregulin, i.e., recombinant human glial growth factor 2 
at room temperature in a humid chamber. Afterwards, the (rhGGF2) (20 ngiml) for 5 min. ErbB4 receptor protein was 
slides were washed in TBS I three times, 10 minutes per immunoprecipitated with an anti-ErbB4 antibody from 500 
wash, to wash off the excess antibody and equilibrated in pg of NRVM lysates or 2000 pg of ARVM lysates, and 
TBS 11 (100 mM Tris, 100 mM NaC1, pH 9.5, 50 mM 65 phosphorylated form of ErbB4 was detected by an anti- 
MgC12.7H20) for 5 minutes. The color substrate was pre- phosphotyrosine antibody. The blot shown in FIG. 1B is 
pared according to the manufacturer's instructions and representative of 3 independent experiments. As shown in 
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FIG. l B ,  phosphorylated ErbB4 is quite prominent in neo- To determine which of the known neuregulin receptors 
natal myocytes and less robust, but detectable, in adult mediate the mitogenic effect of GGF2 on fetal and neonatal 
myocytes, which is consistent with the levels of ErbB4 ventricular myocytes, DNA synthesis was measured in pri- 
mRNA abundance we observed above. PhosPhorYlated mary NRVM cultures after incubation with antibodies spe- 
forms of ErbB2 and ErbB3 Could not be detected even if s cific for ErbB2, ErbB3 and ErbB4. Neonatal myocytes were 
immunoprecipitated with biotinylated-antiphosphotyrosine cultured for two days in serum-free medium, after which 
dances for these two neuregulin receptors in post-natal rhGGF2 ngiml), or with rhFGF2 (20 ngiml), or with 
GGF2iFGF2 and antibodies to ErbB2, ErbB3 or ErbB4, cardiac myocytes. GGF2 Stimulates DNA Synthesis in Neonatal Rat Ventricu- either alone or in as illustrated, (o,5 
lar Myocytes pgimliantibody) were preincubated with cells for 2 h before 
antibody, consistent with the much-reduced mRNA abun- they were treated for 30 h either without (control), or with 
To investigate the ability of GGF2 to DNA 
synthesis in NRVM primary cultures, myocytes maintained 
in serum-free medium for 2 days were subsequently treated 
the addition Of either GGF2 Or FGF2. [3HlThymidine was 
added during the last (data are expressed as 
with 40 ng/ml rhGGF2 for 30 h, DNA synthesis was cpmidish normalized to the mean cpm of control cells in 
monitored by measuring the incorporation of either BrdU IS each experiment, and are presented as mean+SD; n=3 inde- 
(FIG. 2B) or [3H]thymidine (FIGS. 3Aand 3B), which were Pendent experiments; *)  Peo.04 VS rhGGF2 alone; #, P>@1 
added to the media either 24 h or 8 h, respectively, before vs rhGGF2 alone). 
termination of each experiment. As shown in FIG. 4, a monoclonal antibody against the 
FIG. 2A shows myocyte myosin heavy chain in NRVM, extracellular domain of c-neuErbB2, inhibited the GGF2- 
visualized with a TRITC-conjugated goat anti-mouse anti- 20 dependents increase in [3H]thymidine incorporation into 
body (red). FIG. 2B shows BrdU-positive nuclei visualized NRVM by GGF2 could be inhibited. Similarly, an antibody 
with a fluorescein-conjugated mouse anti-BrdU antibody directed against the C-terminus of ErbB4 also blocked about 
(green). The scale bar for FIGS. 2A and 2B is equilvalent to 50% of the increase in [3H]thymidine incorporation induced 
10 pm. FIG. 2C shows the percentage of BrdU-positive by GGF2. A combination of these two antibodies had the 
myocytes under control conditions and in the presence of zs same effect as either the anti-ErbB2 or anti-ErbB4 antibod- 
GGF2 (data are mean+SD for 3 experiments. *, pe0.01). As ies alone. In contrast, an antibody to ErbB3 had no effect on 
displayed in FIG. 2C, 40 ngiml (approximately 0.7 nM) of GGF2-induced DNA synthesis. To verify that the effects 
rhGGF2 increased the percentage of BrdU-labelled myo- seen with the ErbB2 and ErbB4 antibodies were specific for 
cytes (from postnatal day 1 rat heart ventricles) by about GGF, sister NRVM primary cultures were treated with 20 
80%, an increase in magnitude that was similar to that 30 ngiml rhFGF2 (recombinant human bFGF). Neither anti- 
observed with [3H]thymidine incorporation (FIG. 3A). body had any effect on the approximately 2-fold increase in 
FIGS. 3A and 3B show the effects of GGF2 on DNA [3H]thymidine incorporation with rhFGF2. These results 
synthesis in myocyte-enriched and non-myocyte fractions suggest that at least two of the known neuregulin receptor 
from rat ventricular myocyte primary isolates. In FIG. 3A, tyrosine kinases were present and coupled to downstream 
NRVM-enriched primary isolates or a “non-myocyte”- 3s signalling cascades in the neonatal ventricular myocyte. 
enriched fraction (see Methods) were exposed to control GGF2 Promotes Cardiac Myocyte Survival In Vitro 
(i.e., serum-free) medium alone (Ctl) or to medium contain- During development, the net increase in the number of 
ing either 40 ngiml rhGGF2 (GGF) or 7% fetal bovine serum functional embryonic myocytes is dependent on both myo- 
(FBS). In FIG. 3B, concentration-dependent effect of GGF2 cyte proliferative capacity and survival. Therefore, it was of 
on NRVM DNA synthesis is shown. DNA synthesis was 40 interest to determine whether GGF2 could promote survival 
assessed by [3H]thymidine incorporation, and the data are of cardiac myocytes in addition to proliferation. Primary 
expressed as relative cpmidish normalized to the mean cpm cultures of NRVM maintained in serum-free medium, with 
of control cells in each experiment (mean+SD of triplicate or without 10 pM of cytosine arabinoside (AraC), were 
analyses from three independent experiments; *, pe0.01 vs treated with the indicated concentrations of GGF2 for 4 
control). Twenty ngiml of rhGGF2 provoked an approximate 4s days, and the relative numbers of metabolically active cells 
60% increase in [3H]thymidine incorporation into NRVM, were determined by a MTT cell respiration assay (see 
which was about half that observed with 7% FBS. The Methods). Data are expressed as a percentage of the mean 
mitogenic effect of rhGGF2 on NRVM was concentration- MTT activity of myocytes in triplicate culture dishes on day 
dependent, with about an 80% increase at 50 ngiml (i.e., 0.9 0 at the time of the addition of GGF2. Data are shown as 
nM) (FIG. 3B). GGF2 had similar mitogenic effects on BrdU SO mean+SD (n=3 experiments; *, pe0.05 vs control). We 
or [3H]thymidine incorporation on rat embryonic ventricular observed that approximately 25% of cells die by day 4. In 
myocytes (E19) and postnatal ventricular myocytes (P5), contrast, addition of GGF2 resulted in a 30% increase in 
whereas concentrations of GGF2 as high as 100 ngiml had MTT activity compared to controls. The effect was 
no effect on DNA synthesis in adult rat ventricular myocyte concentration-dependent with an EC50 of 0.2 ngiml (FIG. 
primary cultures. ss 5).  This survival effect was observed in NRVM primary 
The effects of rhGGF2 on non-myocyte fractions obtained cultures for up to 7 days; it was also observed in the presence 
following the preplating steps of the neonatal rat ventricular of cytosine arabinoside (AraC), an antiproliferative agent. 
myocyte isolation procedure also were investigated. As As shown in FIG. 5,  the survival effect of GGF2 was 
shown in FIG. 3A, rhGGF2 did not induce any significant observed at 4 days in the continuous presence of cytosine 
change in [3H]thymidine incorporation into non-myocytes. 60 arabinoside, with about 90% myocyte viability in the pres- 
This was in contrast to 7% FBS, which induced nearly a ence of 50 ngiml rhGGF2 compared to approximately 70% 
10-fold increase in [3H]thymidine incorporation into this viability in control cultures. In contrast, GGF2 had no 
cell population. Therefore, GGF2 shows a relatively specific significant effect on the survival of myocyte-depleted, “non- 
action on cardiac myocytes compared to a myocyte-depleted myocyte”-enriched primary isolates at 4 days. 
cell population which, using the method of myocyte isola- 65 We examined next whether the survival effect of GGF2 
tion we employed here, is composed largely of fibroblasts was mediated by inhibition of programmed cell death 
and endothelial cells. (apoptosis). Primary cultures of NRVM 2 days in serum-free 
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medium were maintained in either the absence of rhGGF2 
(FIGS. 6A-6C) or in the presence of 20 ngiml of rhGGF2 
(FIGS. 6E-6G) for 4 days. Cells were then fixed and stained 
myocytes, we examined the effects of GGF2 on induction of 
myocyte hypertrophy in both neonatal and adult rat ven- 
tricular myocyte primary cultures. FIGS. SA and SB show 
with anti-MHC antibody and a mlTC-conjugated second- 
ary antibody to 
photomicrographs of subconfluent NRVM primary isolates 
6A and 6E) Or 5 incubated either without (FIG, SA) or with (FIG, SB) myocytes with fluorescein-conjugated dUTP (i.e., TUNEL) to reveal rhGGF2 (20 ngiml) for 72 h in serum-free medium, after apoptotic cells (FIGS. 6B and 6F). The TUNEL-positive 
myocytes displayed cell shrinkage and chromatin which cells were fixed and stained with an antibody to 
staining (FIGS, 6 c  and 6G). ~~~~~~~i~ was quantified either immunofluorescence microscopy. The scale bar shown in the 
by counting the number of TUNEL-positive myocytes (FIG, lo figure represents 10 pM. After a 72-hr incubation in Serum- 
6D) or by flow cytometry analysis of the sub-G1 fraction free medium with 20 Wiml (i.e.9 0.36 of rhGGF2, 
following propidium iodine-staining of primary NRVM CUI- neonatal cardiac myocytes (NRVM) exhibited a significant 
tures that had been treated for 4 days with the indicated increase in cell size and in myofibrillar development. 
concentrations of rhGGF2 (H). The data shown for FIG. 6D 15 A hypertrophic response in cardiac myocytes is charac- 
and FIG. 6H are given as mean2S.D for three independent terized by a number of phenotypic changes in addition to an 
experiments. The scale bar in FIGS. 6A-6C and 6E-6G increase in cell size, such as an increase in contractile 
represents 10 pM. protein content without cellular proliferation and the 
After 6 days in serum-free medium, about 17% of NRVM re-activation of an ‘‘embryonic” gene program. Therefore, 
maintained under control conditions at low density (i.e., 20 we examined the effects of neuregulin on levels of prepro- 
subconfluent) exhibited evidence of apoptosis as detected by ANF and skeletal a-actin mRNA (transcripts normally 
TUNEL staining, with small condensed nuclei and cell found in relatively low abundance in neonatal and adult 
shrinkage consistent with apoptotic cell death (FIGS. ventricular myocytes), and on [3H]Ieucine incorporation as 
6A-6C and 6E-6G). In the presence of 20 ng/ml rhGGF2, an index of protein synthesis in NRVM primary cultures. 
the number of TUNEL positive myocytes declined to about 25 FIG. 8C shows a Northern blot analysis for prepro-ANF and 
8% (FIG. 6D). The effect of GGF2 on inhibiting apoptosis skeletal a-actin mRNA from total RNA (20 pgilane) from 
was also quantified using flow cytometric analysis of pro- NRVM incubated either with or without rhGGF2 (20 ngiml) 
pidium iodide-labelled NRVM primary cultures. After 4 for the times indicated. Equal loading and transfer of RNA 
days in serum- and insulin-free medium, 22% of NRVM 3o were confirmed by G U D H  hybridization. RhGGF2 (20 
were hypodiploid, consistent with initiation of programmed ngiml) increased mRNAlevels for prepro-ANF and skeletal- 
cell death. In the presence of rhGGF2 at concentrations actin within 60 min, approximately doubling by 16 h. 
above 10 ngiml, less than 10% of NRVM exhibited evidence To test the effect of GGF2 on protein synthesis, NVRM 
of apoptosis (FIG. 6H). were cultured in serum-free medium for 24h, after which 
The survival and antiapoptotic effects of GGF2 on the 35 they were treated with the indicated concentrations of 
adult rat ventricular myocyte (ARVM) were also examined rhGGF2 for 40 h, and pulsed with [3Hlleucine for 8 h before 
by MTT cell respiration assay and TUNEL staining. In the termination of GGF2 stimulation. The incorporation of 
experiment shown in FIG. 7 4  primary cultures of ARVM [3H]leucine at each concentration of GGF2 was normalized 
were maintained in either a serum- and insulin-free medium 4o to the protein content of each dish, and data are expressed as 
(i.e., ‘‘ACCV’, see Methods), or ACCTT medium plus relative cpmidish normalized to the mean cpm of untreated 
GGF2 for 6 days. The number of metabolically active cells control cells in each experiment (mean2S.D.; n=3 experi- 
was determined by the MTT cell respiration assay, and the ments; *, pe0.01 vs control). FIG. SD shows that GGF2 also 
data are expressed as the relative absorbance normalized to stimulated [3Hlleucine incorporation, with about a 120% 
the mean absorbance of untreated, control cells. Each bar 45 increase at 48 h, at a concentration of 5 ngiml. To minimize 
represents the mean2S.D (n=3 experiments; *, pe0.05 vs possible confounding effects of GGF2 on the rate of [3H] 
control). In the experiment shown in FIG. 7B, primary leucine uptake into non-myocyte contaminant cells, these 
cultures of ARVM were maintained in ACCTT medium experiments were repeated in the continuous presence of 
(control) or ACCTT medium plus rhGGF2 (25 ngiml) for 3 
days. After fixation with 4% paraformaldehyde, myocytes GGF2 also caused hypertrophic responses in cultured 
were visualized with an anti-MHC antibody and a TRITC- adult rat ventricular myocytes (MVM). Primary cultures of 
conjugated secondary antibody, and apoptotic cells were ARVM were plated on coverslips in 24-well dishes and 
identified by TUNEL staining. About 500 myocytes were maintained for 5 days in ACCITT medium either without 
counted on each coverslip (data are mean2S.D of three ss (FIG. 9 4  or with rhGGF2 (20 ngiml) (FIGS. 9B and 9C). 
independent experiments; *, pe0.05 versus control). When Cells were fixed in 4% paraformaldehyde, stained with an 
compared to untreated ARVM primary cultures, in which antibody to myosin heavy chain (green, FITC), and exam- 
more than 10% of cells were positive for TUNEL labelling, ined by confocal microscopy. The scale bars represent 10 
rhGGF2 (20 ng/ml)-treated adult myocyte cultures exhibited pM. By 72 h in the continuous presence of 20 ngiml of 
only about 3% TUNEL-positive staining (FIG. 7B). These 6o rhGGF2, Some adult myocytes had begun to develop 
results indicate neuregulins act as survival factors at least in “pseudopod”-like extensions, primarily from the region of 
part by preventing programmed cell death in both neonatal the intercalated discs, and by 5 days, more than 60% of the 
and adult ventricular myocytes. GGF-treated adult cardiomyocytes displayed phenotypic 
GGF2 Induces Hypertrophic Growth of Cardiac Myocytes 65 changes consistent with those illustrated in FIGS. 9B and 
In order to investigate whether neuregulin signalling can 9C, whereas more than 80% of untreated ARVM maintained 
induce a hypertrophic (growth) response in cardiac the phenotype exhibited in FIG. 9A. 
condensation, which were also identified by Hoescht 33258- cardiac MHC (red, TRITC) and examined indirect 
cytosine arabinoside with similar results. 
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GGF2 also enhanced expression of prepro-ANF and skel- 
eta1 a-actin in ARVM. Primary isolates of ARVM were 
stimulated either with or without 20 ngiml rhGGF2 for the 
times indicated. Total RNA was isolated and analyzed by 
Northern blot (25 pg/lane) using prepro-ANF and skeletal Lv Hypertrophy and Hemodynamics 
As shown in Table 1, left ventricular (LV) weight and the 
(a-actin cDNA probes. Equal loading and transfer condi- LV/body weight ratio were significantly (pe0.05) increased 
phrine lo pM) was as a positive for with age-matched controls. The in vivo LV systolic pressure 
Wiml) doubled PrePro-ANF mRNA d ~ n d a n c e  in ARvM aortic stenosis animals compared with age-matched con- 
within 20 h. An increase in skeletal a-actin mRNA abun- 
dance was also observed that was greater than that seen with 
phenylephrine (10 pM), an a-adrenergic agonist known to 
induce hypertrophic growth and reexpression of a number of 
fetal genes in adult rat ventricular myocytes. Within 7 h, 
skeletal a-actin mRNA levels were easily detectable, and 
increased by an additional 250% by 30 h treatment with 20 
GGF2. Neither GGF2 nor phenylephrine had any effect on 
EXAMPLE I11 
ErbB2 and ErbB4 Expression Levels Decrease in 
Aortic Stenosis Rats in Transition From Chronic 
Hypertrophy to Early Heart Failure 
were 'Onfirmed by GAPDH hybridization. in the 6-week and 22-week aortic stenosis animals compared 
hypertrophic growth. As shown in 9D, rhGGF2 (20 lo was significantly increased in both &week and 22-week 
trols, In vivo LV end-diastolic UreSSure was also higher in primary cultures after 8 h, and this had increased 3- to 4-fold 
15 
a 
aortic stenosis animals compared to age-matched controls. 
Consistent with prior studies in this model, LV systolic 
developed pressure per gram was significantly higher in 
6-week aortic stenosis animals in comparison with age- 
matched controls, but depressed in 22-week aortic stenosis 
animals. At 22-week post banding, the aortic stenosis ani- 
mals also showed clinical markers of failure including 
tachypnea, small pleural and pericardial effusions. 
TABLE 1 
Left Ventricular Hypertrophy and Hemodynamics 
C LVH C LVH 
(6 wks) (6 wks) (22-wks) (22 wks) 
BW (SI 397 r 10 378 r 15 590 r 10 564 r 19 
LV Wt (SI 1.25 r 0.05 1.58 r 0.06* 1.64 r 0.07 2.46 r 0.10* 
LV WVBW (gkg) 3.18 r 0.13 4.40 r O X *  2.84 r 0.14 4.41 r 0.20* 
LVEDP (mmHg) 4.8 r 0.3 12.4 r 0.7* 6.5 r 0.8 15.7 r 1.0* 
LV devP/g (mmHgig) 84.2 r 5.2 108.1 r 6.8* 82.4 r 7.8 68.1 r 4.2*- 
LVSP (mmHg) 104 r 3 181 r 7* 129 r 5 182 r 9* 
Table 1 Legend: 
LVH, hearts with left ventricular hypertrophy, 6 and 22 weeks after aortic stenosis; 
C, age-matched controls; 
BW, body weight; 
LV Wt, left ventricular weight; 
LVEDP, LV end-diastolic pressure; 
LVSP, LV systolic pressure; 
LV devP, LV developed pressure per gram. 
Values are mean r SEM; 
*p < 0.05 vs. age-matched controls; 
-p < 0.05 vs. 6-weeks LVH. 
n = 14-20 per group. 
4s  
GAPDH mRNA abundance under the conditions employed 
here. 
Expression of LV ErbB2, ErbB4 and Neuregulin in Aortic 
Stenosis 
Using RT-PCR, we were able to detect ErbB2, ErbB4 and 
neuregulin mRNA, but not ErbB3 mRNA, in LV tissue 
To test the effect of GGF2 on arotein svnthesis. ARVM (2 50 derived from hearts of adult male rats with and without left 
days in ACCITT medium) were stimulated with increasing ventricular hypertrophy, as well as in normal and hYPertr0- 
concentrations of rhGGF2 for 4o and [3H]leucine was phied myocytes. FIG. 10A shows a ribonuclease protection 
assay demonstrating LV ErbB2 and 0-actin mRNA expres- 
sion in 6-week aortic stenosis hearts and controls, and in added during the last 14 h. [3H]Leucine uptake in GGF2- 
uptake in non-stimulated control mYocYtes. Data were also a ribonuclease protection assay demonstrating LV ErbB4 
normalized to protein content of each dish to adjust for any and 0-actin mRNA expression in 6-week aortic stenosis 
variability in cell number among dishes (mean2S.D; n=4; *, hearts and controls, and 22-week aortic stenosis hearts and 
peO.01 vs control). As illustrated in FIG. 9E, GGF2 induced 6o controls. Steady state levels ofErbB2, ErbB4 and neuregulin 
a dose-dependent increase in [3Hlleucine incorporation, mRNA levels in LV tissue from aortic stenosis rats and 
controls (n=5 hearts per group) were then measured by 
with a 70% increase at a concentration of 5 ngiml. Thus, this ribonuclease protection assay (RPA) and normalized to 
hypertrophic adaptation in both rat veri- 65 cantly different in tissue from 6-week aortic stenosis rats 
tricular myocyte phenotypes at subnanomolar concentra- compared to age-matched controls (0.68+0.12 vs. 0.45+0.12 
tions. units, NS) or 22-week aortic stenosis rats compared to 
treated was to the mean Of [3Hiieucine 55 22-week aortic stenosis hearts and controls, FIG, 10B shows 
neuregulin induces phenotypic changes consistent with fl-actin, The LV neuregulin mRNA levels were not signifi- 
and 
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age-matched controls (0.78+0.21 vs. 0.51+0.21 units, NS). 
Moreover, the LV ErbB2 and ErbB4 mRNA levels, which 
6-week aortic stenosis rats with compensatory hypertrophy 
ErbB4 (PCo.01) message levelswere significantly depressed 
in 22-week aortic stenosis rats at the stage of early failure 
(FIG. 10 and Table 2). 
LV ErbB2 and ErbB4 Protein Levels 
Western blotting using polyclonal antibodies for ErbB2 
from LV tissue of 6-week and 22-week aortic stenosis rats in 
comparison with age-matched controls (n=5 per group). 
and 0-actin protein levels in 6-week (FIG. 13A) aortic 
stenosis hearts and controls, and 22-week (FIG. 13B) aortic 
stenosis hearts and controls. FIGS. 13C and 13D show 
were normalized to levels of fj-actin, were preserved in and ErbB4 was performed protein derived 
relative to controls. In contrast, L v  ErbB2 (Pco.05) and FIGS, 13A and 13B show Western blots showing LV ErbB2 
TABLE 2 
LV mRNA and Protein Levels of ErbB Receptors 
C LVH C LVH 
(6 wks) (6 wks) (22-wks) (22 wks) 
mRNA (LV) 
ErbB2 0.354 r 0.016 0.326 r 0.028 0.528 r 0.072 0.301 r 0.027* 
ErbB4 1.158 r 0.036 1.088 r 0.062 1.236 r 0.050 0.777 r 0.082** 
mRNA (mvocvte’l 
ErbB2 0.755 r 0.066 0.683 r 0.027 1.609 r 0.089 0.493 r 0.035** 
ErbB4 0.291 r 0.024 0.266 r 0.012 0.346 r 0.023 0.182 r 0.014** 
protein (LV) 
ErbB2 1.228 r 0.107 1.073 r 0.092 1.218 r 0.198 0.638 r 0.065* 
ErbB4 2.148 r 0.180 1.968 r 0.150 1.446 r 0.119 0.828 r 0.068** 
Table 2 Legend: 
LVH, hearts with left ventricular hypertrophy, 6 and 22 weeks after aortic stenosis; 
C, age-matched controls; 
left ventricular (LV) mRNA levels were measured by ribonuclease protection assay and nor- 
malized to fi-actin; mRNA levels were measured in RNA from both LV tissue (mRNA, LV, n 
= 5 hearts per group) and from LV myocytes (mRNA, myocyte; ErbB2 n = 5 hearts per 
group; ErbB4 n = 3 4  hearts per group). 
LV protein levels were measured in LV tissue (n = 5 per group) by Western blotting and nor- 
malized to fi-actin. 
Values are mean r SEM; 
*p < 0.05 vs. age matched controls; 
**p < 0.01 vs. age-matched controls. 
We next examined gene expression in RNA from LV Western blots showing LV ErbB4 and 0-actin protein levels 
myocytes of 6-week and 22-week aortic stenosis animals in 6-week (FIG. 13C) aortic stenosis hearts and controls, and 
and controls. The specificity of expression in myocytes was 40 22-week (FIG. 13D) aortic stenosis hearts and controls. 
determined by examining message levels of atrial natriuretic Densitometric signals of each receptor were normalized to 
Peptide ( m p ) ,  a Positive molecular marker of Pressure signals of 0-actin. As shown in FIGS. 13A-13D and Table 
overload hypertrophy, using myocyte RNA and normaha- 2, ErbB2 and ErbB4 mRNA expression is preserved relative 
tion to levels of GAPDH. As shown in FIG. 11, ANp was to controls in 6-weeks aortic stenosis animals at the stage of 
upreda ted  in mYocYtes from both &week (710216 VS. 45 compensatory hypertrophy (NS) but ErbB2 (pc0.05) and 
230240 units, pc0.05) and 22-weeks aortic stenosis animals ~ ~ b ~ 4  (pco,ol) are downregulated in 22-week aortic steno- 
(898252 vs. 339213 units, PC0.O5) in with sis animals during early failure. Thus, a decrease in both LV 
controls (n=5 Per group). Neured in  was not detectable by message and protein levels of ErbB2 and ErbB4 is present 
RPA in RNA derived from myocytes in any group. at the stage of early failure in this model of pressure 
message levels were also measured in myocyte RNA from situ Hybridization for ~ ~ ~ ~ ~ ~ ~ l i ~  
both aortic stenosis groups (FIG. 12 and Table 2). FIG. 12A Antisense digoxigenin-labeled m~~~ of neuregulin gen- 
shows a ribonuclease protection assay demonstrating LV erated reproducible hybridization signals on  LV 
ErbB2 and fl-actin mRNA in cryosections, whereas the corresponding sense transcript 
aortic stenosis hearts and controls, and 22-weeks aortic ss generated no signal above background, ~ ~ ~ ~ ~ ~ ~ l i ~  signals 
stenosis hearts and controls. FIG. 12B shows a ribonuclease in adult heart cryosections were observed in the endothelial 
Protection assay demonstrating L v  myocyte ErbB4 and cells of the cardiac microvasculature with minimal or no 
0-actin mRNA expression in 6-week aortic stenosis hearts signal in other cell compartments, There was no difference 
and controls, and 22-week aortic stenosis hearts and con- between control and aortic stenosis animals, 
trols. Consistent with the measurements in LV tissues 60 
samples, cardiomyocyte ErbB2 and ErbB4 mRNA levels, 
normalized to 0-actin levels, are preserved relative to con- 
trols in 6-week aortic stenosis animals at the stage of 
compensatory hypertrophy (NS). However, both ErbB2 and 
ErbB4 expression are significantly downregulated in 65 
22-week aortic stenosis animals at the transition to failure 
(pcO.01). 
ErbB2 (n=5 per group) and ErbB4 ( n = 3 4  per group) SO overload, 
EXAMPLE IV 
Inhibition of Heart Failure in Aortic Stenosis Mice 
by Polypeptides That Contain a Neuregulin-1 EGF- 
like Domain 
The Examples above describe data showing that rhGGF2 
suppresses apoptosis and stimulates cardiomyocyte hyper- 
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trophy in an ErbB2- and ErbB4-dependent fashion. 
Moreover, ErbB2 and ErbB4 receptors are down-regulated 
in the left ventricles of rats with pressure overload-induced 
heart failure. Cardiomyocyte apoptosis is extremely rare 
during the early compensatory hypertrophic stage in aortic 
stenosis mice (i.e., 4 weeks after aortic banding), but con- 
sistently appears during the transition to early heart failure 
(i.e., 7 weeks after aortic banding). 
These above observations indicate that administration of 
polypeptides that have an EGF-like domain encoded by a 
neuregulin gene will be useful in inhibiting the progression 
of and/or protecting against congestive heart failure. While 
not wishing to be bound by theory, it is likely that neuregulin 
treatment will strengthen the pumping ability of the heart by 
stimulating cardiomyocyte hypertrophy, and partially or 
completely prevent further deterioration of the heart by 
suppressing cardiomyocyte apoptosis. 
One of ordinary skill in the art can readily determine the 
optimal dosage regimen required for providing prophylaxis 
against congestive heart disease or for slowing or halting 
progression of already-existent heart disease, using one of 
the many animals models for congestive heart failure that 
are known in the art. For example, as a starting point, the 
relative efficacy of a 0.3 m a g  dose of GGF2 administered 
at early stages and late stages of cardiac disease in the aortic 
stenosis mouse model may be assessed as follows. 
Group 1 (n=6); treated: injections of rhGGF2 (0.3 m a g  
given on alternate days), initiated 48 hours after aortic 
banding and continued through week 7. 
Group 2 (n=6); treated: injections of rhGGF2 (0.3 m a g  
given on alternate days), initiated at the beginning of week 
4 after aortic banding and continued through week 7. 
Group 3 (n=6); control: sham injections, initiated 48 hours 
after aortic banding and continued through week 7. 
Group 4 (n=6); control: sham injections, initiated at the 
beginning of week 4 after aortic banding and continued 
through week 7. 
Animals are sacrificed at the end of week 7. Prior to 
sacrifice, left ventricular hemodynamics are measured as 
described in Example I above, or using any standard pro- 
tocol. Confocal microscopy may be used to quantitate myo- 
cyte growth (hypertrophy) and myocyte apoptosis by in situ 
nick-end labeling (TUNEL) or similar techniques for mea- 
suring cell death, using standard protocols or as described in 
Example I. 
One of skill in the art will fully comprehend and know 
how to perform the experiments needed to determine the 
optimal neuregulin dosage regimen (e.g., amount of dose, 
frequency of administration, optimal time during the disease 
course to initiate neuregulin treatment) for minimizing, 
preventing, or even reversing congestive heart disease. 
EXAMPLE V 
NRG-1 Inhibits Anthracycline-induced Apoptosis in 
Rat Cardiac Myocytes 
The anthracycline antibiotics (e.g., daunorubicin, and 
doxorubicin) have been a mainstay of cancer chemotherapy 
for more than 20 years. However, the short- and long-term 
cardiotoxicity of these drugs limits both the individual dose 
and the cumulative dose that can be delivered to a patient. 
There are two clinical types of anthracycline-induced 
cardiotoxicity. The acute type, which can occur after a single 
dose of anthracycline, is characterized by electrocardio- 
graphic changes, arrhythmias, and a reversible decrease in 
26 
ventricular contractile function. The chronic, delayed type is 
characterized by a largely irreversible decrease in ventricu- 
lar contractile function which progresses to dilated cardi- 
omyopathy and congestive heart failure. The incidence of 
s this chronic cardiotoxicity is in direct proportion to the 
cumulative anthracycline dose. 
We have found that GGF2 (NRG-1) inhibi ts  
anthracycline-induced apoptosis in rat cardiac myocytes. 
FIG. 14 shows that rat cardiomyocyte cultures pre-treated 
10 with IGF-1 or NRG-1 are less susceptible to apoptosis 
(indicated by TUNEL staining) induced by 1 pM daunoru- 
bicin. For IGF-1 this protective effect is rapid, and can be 
achieved within 30 minutes of pre-incubation, similar to 
what was reported for fetal cardiac myocytes. In contrast, 
FIG. 15Ashows that both IGF-12 and NRG-1 cause rapid 
phosphorylation of Akt (FIG. 15A), and that this is inhibited 
by the PI-3 kinase inhibitor wortmannin. Akt has been 
implicated in mediating survival signals in some systems 
2o through phosphorylation and inactivation of the pro- 
apoptotic protein caspase 3. Either thirty minutes of pre- 
incubation with IGF-1 or 24 hours of pre-incubation with 
NRG-1 prevent anthracycline-induced activation of caspase 
3. This effect, as well as the survival effect of IGF-1, is 
25 completely prevented by wortmannin (FIG. 15B). Thus, 
activation of PI-3 kinase is necessary for the cytoprotective 
effect of IGF on myocytes. However, the lack of cytopro- 
tection by NRG-1 over the same time course indicates that 
activation of PI-3 kinase and Akt is not sufficient for 
30 cytoprotection. The relatively long NRG-1 exposure period 
needed for cytoprotection suggests that NRG-1-dependent 
protection of cardiomyocytes against apoptosis requires de 
novo protein synthesis. Consistent with this observation, 
treatment of the cells with cyclohexamide inhibits the anti- 
The results described above show that NRG-1 effectively 
inhibits anthracycline-induced apoptosis. Therefore, NRG-1 
could be used to limit or prevent cardiotoxicity in patients 
4o undergoing anthracycline chemotherapy and to treat patients 
that have congestive heart failure caused by cardiotoxicity 
induced by anthracyclines or other cardiotoxic agents. 
Existing in the art are various well known animal models 
of anthracycline-induced cardiotoxicity. Mouse, rat, rabbit, 
45 hamster, dog, swine, and monkey models for assessing the 
relative efficacy of therapeutic compounds for ameliorating 
anthracycline-induced cardiotoxicity are described in “Ame- 
lioration of Chemotherapy Induced Cardiotoxicity” Semin. 
Oncol. 25(4)Suppl. 10, August 1998 (see, e.g., Myers, 
so Semin. Oncol. 25:lO-14,1998; Herman and Ferrans, Semin. 
Oncol. 25:15-21, 1998; and Imondi, Semin. Oncol. 
25:22-30, 1998). These models may be used to determine 
the optimal neuregulin or neuregulin-like polypeptide treat- 
ment regimen (e.g., amount and frequency of dosage, and 
55 timing relative to anthracycline administration), for 
minimizing, preventing, or reversing anthracycline-induced 
cardiotocicity. 
15 this effect takes 24 hours of pre-incubation with NRG-1. 
35 apoptotic effect of NRG-1 on cardiomyocytes. 
EXAMPLE VI 
Neuregulin-dependent Inhibition of Cardiac Failure 
Induced by Anthracyclineianti-ErbB2 (anti-HER2) 
Combination Therapy 
60 
Various types of cancer cells display increased expression 
65 or increased biological activity of ErbB receptors. These 
transmembrane receptor tyrosine kinases bind growth fac- 
tors belonging to the neuregulin (also known as heregulin) 
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family. Expression of the ErbB2 receptor (also known as would be greatly improved if its associated cardiotoxicity 
HER2 and neu) in cancer cells has been correlated with could be decreased or prevented. 
increases in proliferation of carcinoma cells derived from 
various tissues, including, but not limited to, breast, ovary, Animal models of anthracycline-induced cardiotoxicity 
prostate, colon, pancreas, and salivary gland. (see, e.g., Herman and Ferrans, Semin. Oncol. 25:15-21, 
1998 and Herman et al. Cancer Res. 58:195-197,1998) are Recently, it has been shown that HERCEPTINB 
well-known in the art. Moreover, antibodies that block (Trastuzumab; Genentech, Inc., South San Francisco, 
Calif.), a humanized monoclonal antibody that specifically neuregulin binding to ErbB2 such as those 
binds the extracellular domain of the human ErbB2 (HER2) described a re  By inducing 
receptor, inhibits the growth of breast carcinoma cells in anthracyclineianti-ErbB2 antibody-dependent heart failure 
vitro and in vivo by down-regulating ErbB2 activity, A in known animal models for anthracycline toxicity, one of 
phase 111 clinical trial evaluating the safety and eficacy of skill in the art will readily be able to determine the neu- 
cycline (doxorubicin) chemotherapy in breast cancer such heart 
patients showed that patients receiving the combination 15 
therapy displayed greater tumor shrinkage and inhibition of 
cancer progression than patients receiving either therapy 
combining HERCEPTINB therapy with traditional anthra- regu1in dosage regimen required to minimize Or prevent 
Other Embodiments 
alone. However, patients receiving combination therapy also mentioned in this 
suffered increased cardiotoxicity relative to patients receiv- specification are herein incorporated by reference to the 
ing anthracycline therapy alone, indicating that anti-ErbB2 20 Same extent as if each independent publication or patent 
(anti-HER2) antibodies such as HERCEPTINB increase application was specifically and individually indicated to be 
anthracycline-induced cardiotoxicity. In addition, patients incorporated by reference. 
that had previously been treated with doxorubicin and later While the invention has been described in connection 
received HERCEPTINB also showed an increased inci- with specific embodiments thereof, it will be understood that 
dence of cardiotoxicity, relative to patients treated with 2s it is capable of further modifications and this application is 
doxorubicin alone. intended to cover any variations, uses, or adaptations of the 
Given the recently-shown success of HERCEPTINBi invention following, in general, the principles of the inven- 
anthracycline combination therapy in ameliorating ErbB2- tion and including such departures from the present disclo- 
overexpressing breast tumors, it is likely that similar com- sure come within known or customary practice within the art 
bination therapies will soon be used to treat other ErbB2- 30 to which the invention pertains and may be applied to the 
overexpressing tumors. However, the benefitirisk ratio of essential features hereinbefore set forth, and follows in the 
anti-ErbB2 antibodyianthracycline combination therapy scope of the appended claims. 
publications and patent 
SEQUENCE L I S T I N G  
< 1 6 0 >  NUMBER O F  S E Q  I D  NOS: 1 0  
< 2 1 0 >  S E Q  I D  NO 1 
< 2 1 1 >  LENGTH: 25  
< 2 1 2 >  TYPE:  DNA 
< 2 1 3 >  ORGANISM: A r t i f i c i a l  Sequence 
<2 2 0 > FEATURE : 
< 2 2 3 >  OTHER INFORMATION: B a s e d  on R a t t u s  norvegicus  
<400>  SEQUENCE: 1 
t g t g c t a g t c  aagagtccca accac 
< 2 1 0 >  S E Q  I D  NO 2 
< 2 1 1 >  LENGTH: 25  
< 2 1 2 >  TYPE:  DNA 
< 2 1 3 >  ORGANISM: A r t i f i c i a l  Sequence 
<2 2 0 > FEATURE : 
< 2 2 3 >  OTHER INFORMATION: B a s e d  on R a t t u s  norvegicus  
<400>  SEQUENCE: 2 
c c t t c t c t c g  g t a c t a a g t a  t t c a g  
25  
25  
< 2 1 0 >  S E Q  I D  NO 3 
< 2 1 1 >  LENGTH: 25  
< 2 1 2 >  TYPE:  DNA 
< 2 1 3 >  ORGANISM: A r t i f i c i a l  Sequence 
<2 2 0 > FEATURE : 
< 2 2 3 >  OTHER INFORMATION: B a s e d  on H o m o  sap iens  
<400>  SEQUENCE: 3 
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- con t inued  
g c t t a a a g t g  c t t g g c t c g g  g t g t c  
< 2 1 0 >  S E Q  I D  NO 4 
< 2 1 1 >  LENGTH: 24 
< 2 1 2 >  TYPE:  DNA 
< 2 1 3 >  ORGANISM: A r t i f i c i a l  Sequence 
<220> FEATURE: 
< 2 2 3 >  OTHER INFORMATION: B a s e d  on Homo sap iens  
<400>  SEQUENCE: 4 
tcctacacac t g a c a c t t t c  t c t t  
< 2 1 0 >  S E Q  I D  NO 5 
< 2 1 1 >  LENGTH: 2 6  
< 2 1 2 >  TYPE:  DNA 
< 2 1 3 >  ORGANISM: A r t i f i c i a l  Sequence 
<220> FEATURE: 
< 2 2 3 >  OTHER INFORMATION: B a s e d  on Homo sap iens  
<400>  SEQUENCE: 5 
aattcaccca tcagagtgac  g t t t g g  
< 2 1 0 >  
< 2 1 1 >  
< 2 1 2 >  
< 2 1 3 >  
<220> 
< 2 2 3 >  
<400>  
S E Q  I D  NO 6 
LENGTH: 2 3  
TYPE:  DNA 
ORGANISM: A r t i f i c i a l  Sequence 
FEATURE : 
OTHER INFORMATION: B a s e d  on Homo sap iens  
SEQUENCE: 6 
t c c t g c a g g t  a g t c t g g g t g  c t g  
< 2 1 0 >  S E Q  I D  NO 7 
< 2 1 1 >  LENGTH: 24 
< 2 1 2 >  TYPE:  DNA 
< 2 1 3 >  ORGANISM: A r t i f i c i a l  Sequence 
<220> FEATURE: 
< 2 2 3 >  OTHER INFORMATION: B a s e d  on R a t t u s  norvegicus 
<400>  SEQUENCE: 7 
gc tggc tccg  a t g t a t t t g a  t g g t  
< 2 1 0 >  S E Q  I D  NO 8 
< 2 1 1 >  LENGTH: 24 
< 2 1 2 >  TYPE:  DNA 
< 2 1 3 >  ORGANISM: A r t i f i c i a l  Sequence 
<220> FEATURE: 
< 2 2 3 >  OTHER INFORMATION: B a s e d  on R a t t u s  norvegicus 
<400>  SEQUENCE: 8 
g t t c t c t g c c  g t a g g t g t c c  c t t t  
< 2 1 0 >  S E Q  I D  NO 9 
< 2 1 1 >  LENGTH: 22 
< 2 1 2 >  TYPE:  DNA 
< 2 1 3 >  ORGANISM: A r t i f i c i a l  Sequence 
<220> FEATURE: 
< 2 2 3 >  OTHER INFORMATION: B a s e d  on Homo sap iens  
<400>  SEQUENCE: 9 
gca tcac tgg  c t g a t t c t g g  ag 
2 5  
2 4  
2 6  
2 3  
2 4  
2 4  
2 2  
< 2 1 0 >  S E Q  I D  NO 1 0  
< 2 1 1 >  LENGTH: 22 
< 2 1 2 >  TYPE:  DNA 
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- con t inued  
< 2 1 3 >  ORGANISM: A r t i f i c i a l  Sequence 
<220> FEATURE: 
< 2 2 3 >  OTHER INFORMATION: B a s e d  on Homo sap iens  
<400>  SEQUENCE: 1 0  
cacatgccgg t t a t g g t c a g  ca 2 2  
What is claimed is: 9. The method of claim 4, wherein said cardiotoxic 
1. A method for treating or preventing congestive heart compound is an anti-ErbB2 or anti-HER2 antibody. 
failure in a mammal, said method comprising administering 10. The method of claim 4, wherein said polypeptide is 
a polypeptide comprising an epidermal growth factor-like administered prior to exposure to said cardiotoxic com- 
(EGF-like) domain to said mammal, wherein said EGF-like pound. 
domain is encoded by the neuregulin (NRG)-J gene, wherein 11. The method of claim 4, wherein said polypeptide is 
said administering is in an amount effective to treat or administered during exposure to said cardiotoxic compound. 
prevent heart failure in said mammal. 12. The method of claim 4, wherein said polypeptide is 
2. The method of claim 1, wherein said polypeptide is 2o administered after exposure to said cardiotoxic compound. 
recombinant human GGF2. 13. The method of claim 1, wherein said polypeptide is 
3. The method of claim 1, wherein said mammal is a administered prior to the diagnosis of congestive heart 
human. failure in said mammal. 
4. The method of claim 1, wherein said congestive heart 14. The method of claim 1, wherein said polypeptide is 
failure results from hypertension; ischemic heart disease; 2s administered after the diagnosis of congestive heart failure 
exposure to a cardiotoxic compound; myocarditis; thyroid 
disease; viral infection; gingivitis; drug abuse; alcohol 15. The method of claim 1, wherein said polypeptide is 
abuse; periocarditis; atherosclerosis; vascular disease; administered to a mammal that has undergone compensatory 
in said mammal. 
hypertrophic cardiomyopathy; acute myocardial infarction; 
left ventricular systolic dysfunction; coronary bypass sur- 
gery; starvation; an eating disorder; or a genetic defect. 
5. The method of claim 4, wherein said mammal has 
undergone a myocardial infarction. 
6. The method of claim 4, wherein said cardiotoxic 
compound is an anthracycline; alcohol; or cocaine. 
7. The method of claim 6, wherein said anthracycline is 
doxorubicin, or daunomycin. 
8. The method of claim 7, wherein an anti-ErbB2 or 
anti-HER2 antibody is administered to said mammal before, 
during, or after anthracycline administration. 
cardiac hypertrophy. 
polypeptide maintains left ventricular hypertrophy. 
progression of myocardial thinning. 
3o 16. The method of claim 1, wherein administration of said 
17. The method of claim 1, wherein said method prevents 
18. The method of claim 1, wherein administration of said 
19. The method of claim 1, wherein said polypeptide is 
administered by administering an expression vector encod- 
ing said polypeptide to said mammal. 
3s polypeptide inhibits cardiomyocyte apoptosis. 
* * * * *  
